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1.1 INTRODUCTION AND THESIS OVERVIEW 
 
Pulmonary hypertension (PH), a pathophysiologic condition defined by a mean pulmonary 
artery pressure (mPAP) of >25mmHg measured at rest by right heart catheter (RHC), can 
complicate a range of respiratory, cardiac, and systemic diseases (Figure 1)[1]. Pulmonary 
arterial hypertension (PAH; Group 1 PH) is characterized by a pathological rise in the 
resistance of the pulmonary circulation due to obliterative plexogenic lesions at the proximal 
microcirculatory level.  This distinct pulmonary vascular pathophenotype is diagnosed by the 
presence of pre-capillary PH (mean pulmonary arterial wedge pressure [mPAWP] <15mmHg 
and pulmonary vascular resistance [PVR] >3 Wood Units) and the absence of significant lung 
disease (Group 3 PH) or chronic thromboembolic disease (Group 4 PH).  PAH is considered 
a rare disease with an annual incidence of approximately 2.4 – 10 cases per million per year, 
with about half being sporadic (idiopathic), heritable, or drug-induced, while systemic 
sclerosis is the most common cause of associated PAH (APAH) [2-4].    
 
Occlusive pulmonary vascular lesions are caused by excessive vasoconstriction, arterial wall 
remodelling, and in situ thrombosis propagated by pathological interactions between growth 
factors and their receptors, neurohormones, inflammatory cytokines, endothelial cell 
dysfunction, and dysregulated cell growth and division.  Loss of effective pulmonary 
vascular cross-sectional area increases pulmonary vascular resistance (PVR) and total RV 
afterload, placing undue stress on the RV.  Therefore, while first and foremost a pulmonary 
‘vasculopathy’, morbidity and mortality is closely linked to the functional capacity of the 
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stressed RV.  Over the past two decades, advances in disease understanding and an enriched 
therapeutic armamentarium have improved clinical outcomes but PAH remains a progressive, 
incurable disease with an unacceptably high short-term mortality (3-year median survival 
rates of 58% - 72%), predominantly due to RV failure [5, 6]. 
 
Given the absence of curative treatments, there is a pressing need to identify means by which 
to improve clinical outcomes using current therapies. The goal of the present body of work is 
to investigate whether a standardised, non-invasive pulmonary vasoreactive challenge 
utilizing cardiac magnetic resonance imaging (CMR) and intravenous adenosine infusion can 
provide novel insight into the status of the pulmonary vascular bed, the RV, and their 
interaction (i.e. the cardiopulmonary unit), and to determine whether this may afford a means 
to detect early pulmonary vascular disease (i.e. before measureable resting pulmonary 
haemodynamic abnormalities arise) and objectively monitor disease progression over time.  
The ability to detect early PVD would represent a paradigm shift in how PAH is defined and 
managed, while a standardized, unified method to assess disease progression and treatment 
response would facilitate timely clinical decision-making (e.g. institution of advanced 
medical therapies such as parenteral prostanoids, or referral for lung transplantation).  
 
The present Chapter details physiologic principles underlying the protocol design including a 
discussion regarding the paradigm of early disease detection, current screening practices and 
their limitations, exercise pulmonary haemodynamic assessment of PVD, prognostic 
importance of acute vasoreactivity testing, the concept of pulmonary flow reserve (PFR), and 
limitations of current risk assessment in established PAH.  The importance of functional 
adaptation of the RV is addressed, with emphasis on the relationships between RV coronary 
perfusion, RV remodelling and performance, and cardiopulmonary reserve.   
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Since this body of work is centred around a novel, non-invasive pulmonary vasoreactive 
protocol, a separate (brief) methodology section is provided in Chapter 2.  Here, cardiac 
magnetic resonance imaging sequences, adenosine infusion dosing, and the invasive 
vasoreactivity protocol are outlined and justified.   
 
Chapters 3-5 comprise the results section of the thesis.  Chapter 3 details findings from the 
baseline assessment of the study cohorts including safety and tolerability of the protocol, 
validity of CMR findings using invasive haemodynamics during vasoreactivity as the 
comparator, and the application of findings towards detection of early PVD.  Chapter 4 
details relationships between CMR-derived parameters measured at rest and during 
adenosine-stress with validated invasive and non-invasive prognostic markers used in 
established PAH.   This chapter covers findings from the initial assessment, as well as 
longitudinally over a 6-month period.    
 
Chapter 5 focuses on the relationships between coronary micro- and macro-vascular status 
measured by CMR-derived coronary sinus flow reserve and RHC-derived myocardial 
supply:demand indexes, PVD burden (RV afterload), RV remodelling and performance, and 





Figure 1: Clinical classification of pulmonary hypertension.   




1.2.1 EARLY DETECTION OF PAH 
 
The healthy pulmonary vascular bed is a low pressure, low resistance circuit with high 
capacitance and large microcirculatory reserve which, even during exercise, can 
accommodate high cardiac output (CO) with minimal impact on pressure [8, 9].  Obstruction 
of the vascular bed in the context of PVD can progress unnoticed until the recruitable 
circulatory reserve is overwhelmed.  Following the loss of approximately 50% of the 
microcirculation, symptoms typically develop (usually exertional dypnoea) and measureable 
changes in resting pulmonary haemodynamics arise (Figure 2) [10, 11].  This, combined with 
the often-lengthy delay between symptom onset PAH diagnosis [12], ensures that the 
vasculopathic burden is uniformly high at diagnosis, even if haemodynamic perturbations are 







Figure 2:  Schema of PAH progression (PVD = pulmonary vascular disease).   
Reprinted with permission, source [10]. 
 
While the duration between onset of PVD, development of clinical symptoms, and presence 
of diagnostic haemodynamic abnormalities is unclear, data supports the hypothesis that 
earlier intervention with effective medical therapies improves clinical outcomes in those with 
PAH.  This is perhaps a logical concept given targeted therapies (endothelin receptor 
antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase activators, and 
prostacyclin analogues) exert antiproliferative and antimitogenic effects in addition to potent 
vasodilation, and should, therefore, ameliorate the natural history of the disease [13].  This is 
supported by clinical trial data showing PAH therapies delay clinical worsening and improve 
long term outcomes, even in ‘mild’ disease (i.e. NYHA Class II) }[14-16].  Data for the 
recent AMBITION trial showed improved survival with initial combination therapy 
(ambrisentan and tadalafil) over monotherapy (tadalafil) [17].  In APAH, patients with 
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clinically advanced disease (functional class III/IV) at diagnosis had significantly worse 
prognoses than those with mild symptoms [18-20] [21].  Finally, follow up to the ItinerAir 
study showed scleroderma-associated PAH identified through active screening had better 
survival when compared to a parallel group identified through standard clinical practice [22], 
and while this study was limited by lead-in bias and small numbers, it provides conceptual 
support for early intervention. 
 
Identifying disease early with a view to intervening and mitigating progression requires a 
screening process which, ideally, should be non-invasive, safe, effective, cheap cost effective, 
observer independent, standardised, sensitive and specific, and widely available.  Any 
screening strategy must target certain populations with a sufficiently high absolute risk of the 
target disease to avoid high rates of false positive and negative results.  Current international 
guidelines recommend screening for PAH in patients with systemic sclerosis (SSc), bone 
morphogenic protein receptor type 2 (BMPR2) mutation carriers or their first-degree relatives 
(heritable PAH), and those with portal hypertension referred for liver transplantation [7].   
Prevalence of PAH in the general population is estimated at 15-60 cases per million (up to 
0.006%) [2] compared with 8-10% in the SSc population, 20% in BMPR2 mutation carriers, 
and 0.5-10% in portal hypertension, and absolute lifetime risk for PAH is sufficiently high in 
these groups to warrant screening (10-20%) [2, 3, 23-25].   
 
Since there is no validated method to detect early PVD (i.e. before haemodynamic 
abnormalities arise), established screening tests target the non-invasive identification of PH 
and its sequelae (e.g. right heart strain).  Transthoracic Doppler echocardiography (TTE) is 
the cornerstone of this approach, using the simplified Bernoulli equation to estimate the 
pulmonary arterial systolic pressure (PASP) from the tricuspid regurgitant jet velocity (TRV) 
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and estimated right atrial pressure (RAP; estimated by assessing inferior vena cava size and 
collapsibility with inspiration).  While widely available, cheap, and safe, it is limited by 
sonographer experience, body habitus, image quality, and the dependence on an adequate TR 
Doppler profile, which may be unobtainable in 10-20% of patients being assessed for 
possible PH [26].  There are also concerns regarding the precision of TTE-estimated 
pulmonary pressures [27, 28], particularly at lower TR jet velocities [29].  The performance 
of resting TTE to identify PH is also highly dependent upon the chosen threshold for the 
TRV.  A prospective study in SSc patients found PH could be reasonably detected using a 
TRV of >3 meters/second (m/s) irrespective of symptoms, or 2.5-3 m/s in conjunction with 
unexplained dyspnoea, although false positives (and excess RHCs) were high at about 45% 
[23].  Current European guidelines suggest a high echocardiographic probability for PH when 
the TRV is >3.4 m/s or 2.9-2.4 m/s with other signs of PH (e.g. dilated RV, flattened 
interventricular septum, enlarged RA, high estimated RAP); intermediate with TRV 2.9-3.4 
m/s or ≤2.8 m/s with other PH signs; and low when TRV ≤2.8 m/s without other PH signs 
(Figure 3). 
 
Figure 3: Echocardiographic probability of PH.   
Reprinted with permission, source [7]. 
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Other screening tools include lung function testing (principally assessing the diffusing 
capacity of the lungs for carbon monoxide [DLCO] which, if reduced, may suggest a low 
pulmonary capillary blood volume due to PVD) and serum levels of N-terminal pro-brain 
natriuretic peptide (NT-proBNP), which rise with ventricular volume and pressure overload 
[30].  An increased risk of PAH in SSc patients with a DLCO 60%, an elevated NT-proBNP 
alone, or an elevated NT-proBNP in conjunction with a low DLCO has been demonstrated, 
although both tests lack the necessary sensitivity and specificity for PH to be used in isolation 
[23] [31-33].  Screening algorithms employing a combination of tools have been studied with 
variable reported success [34-38], although all studies were limited by an inability to 
determine the false negative rate as RHC was not performed in control groups.  Furthermore, 
entry criteria often favoured more symptomatic patients with higher pre-test suspicion for 
PAH.    
 
The cross-sectional, multi-centre DETECT trial was the first to address the false negative rate 
of a screening algorithm [39].  Patients with SSc for >3 years and DLCO <60% underwent a 
range of non-invasive investigations including clinical assessment, serum biomarkers, 
electrocardiography, and resting TTE before proceeding to RHC.  PAH was found in 87 of 
the 466 patients (19%) and was mild in the majority (64% WHO functional I/II). The best 
discriminatory variables for PAH detection were determined and a two-step algorithm was 
proposed: step 1 determined referral for resting TTE based on six simple clinical variables, 
and step 2 determined referral for RHC based on the step 1 risk score and subsequent TTE 
findings.  Internal validation showed that 62% of patients would be referred for RHC, with a 
sensitivity of 96% and specificity of 48% for PAH detection (false negative rate of 4%).  This 
outperformed European guideline recommendations of annual echocardiography in 
symptomatic SSc patients, with a higher sensitivity and similar specificity [40], although it 
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remains unclear how to proceed in patients with a DLCO >60% and the algorithm lacks 
validation in larger cohorts. 
 
1.2.2 EARLY DETECTION OF PVD 
 
Exercise Pulmonary Haemodynamics 
As noted, established screening programs target non-invasive detection of PH or its sequelae.  
Presently, no validated method exists to reliably identify PVD prior to overt PAH. A rational 
method to detect early stages of disease, with a view to intervening before adverse 
consequences arise, is to assess for an impaired ‘reserve’ by stressing the relevant system and 
detecting abnormal physiologic responses.   Since symptoms with exertion precede 
symptoms at rest and an impaired pulmonary vascular reserve precedes PAH, 
pathophysiologic rationale for exercise haemodynamic testing of patients with suspected 
PAH/early PVD is impeccable, but is limited by several factors.  Firstly, pulmonary 
haemodynamic changes during exercise are complex and less well understood than the 
systemic circulation, and the bounds of ‘normal’ physiology are unclear.  Exercise-induced 
PH (eiPH) was originally defined as a mPAP>30mmHg during exercise [41] until it was 
observed that this threshold was not uncommon in ‘normal’ individuals and was often 
exceeded in conditioned athletes [42-44]. This is explained by the mPAP being dependent on 
PVR, left atrial pressure (LAP), and cardiac output (CO), so that significant CO 
augmentation (e.g. athletes) or an abnormal PVR (e.g. PVD) response can similarly elevate 
mPAP during exercise, even when LAP response is normal.   
 
A more discerning method to detect a compromised pulmonary circulation is to analyse the 
slope reflecting the multi-point relationship between flow (CO) and pressure (mPAP) 
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acquired during incremental exercise [10, 45].  In this context, a steeper than normal slope 
would be expected (i.e. pressure rising rapidly in relation to flow, assuming a normal LAP 
response) due to a blunted capacity to recruit the pulmonary microcirculation [42]. While 
Castelain et al have shown a decrease in this slope after six weeks of IV epoprostenol therapy 
in treatment-naïve patients with severe PAH (Figure 4)  - despite no change in resting 
haemodynamics but a rise in exercise capacity [45] - its application to the detection of early 
PVD is hampered by an incomplete understanding of a normal slope [43] and a dependence 
on invasive measurements.   
 
 
Figure 4: Relationship between mPAP and cardiac index in iPAH patients at baseline and 
after 6 weeks IV prostacyclin therapy.  The pressure-flow slope declined after therapy despite 
no significant change in resting pulmonary haemodynamics but a significant improvement in 
exercise capacity.   
Formatted: Centered, Line spacing:  Double
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Reprinted with permission of the American Thoracic Society. Copyright © 2018 American Thoracic 
Society, Castelain V, Chemla D, Humbert M, Sitbon O, Simonneau G, Lecarpentier Y, Herve P. 
Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. 
American journal of respiratory and critical care medicine. 2002;165:338-40.  The American Journal 
of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society. 
 
Exercise Doppler echocardiography provides an attractive method to non-invasively assess 
exercise pulmonary haemodynamics [46, 47] but is constrained by technical limitations (e.g. 
sonographer-dependence, difficulty obtaining appropriate acoustic windows, particularly of 
the RV); a paucity of data regarding the normal TRV during exercise and the influence of 
age, gender, and body mass; concerns regarding the precision and accuracy of PAP 
estimation from the TRV [27]; lack of a standardized exercise protocol; and, an incomplete 
understanding of the natural history of eiPH (i.e. the risk of incident PAH, and potential 
influence of heterogeneity depending on the underlying aetiology) [20, 48].  Consequently, 
TTE is not suitable as a stand-alone tool for baseline or follow-up assessment of RV function 
and haemodynamics in PAH, and exercise Doppler echocardiography is not recommended by 
guidelines for PAH screening [7]. 
 
In summary, pathophysiologic rationale for exercise testing patients at risk of latent or early 
PVD, with a view to detecting an ‘abnormal’ pulmonary vascular haemodynamic response, is 
sound but limited by difficulties standardizing the exercise protocol (introducing 
heterogeneity between patients and centres); accurately and reproducibly measuring 
haemodynamic changes non-invasively during exercise; defining an ‘abnormal’ pulmonary 
vascular response; and an incomplete understanding of the natural history of eiPH, which in 
part is related to the preceding limitations which introduce significant heterogeneity to 
available data.   Rationale for the novel, non-invasive pulmonary vasoreactive challenge 
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assessed in the present body of work is grounded in addressing some of these limitations.  
The following sections will discuss and justify the chosen imaging modality, measurement 
parameters of interest, and method for ‘stressing’ the cardiopulmonary unit.   
 
 1.2.3 A NOVEL APPROACH 
Cardiac magnetic resonance imaging 
Cardiac magnetic resonance imaging (CMR), first utilised in PH more than 30 years ago [49], 
has become the gold-standard non-invasive method to measure RV structure and function in 
PAH [50, 51] with applications in diagnosis, risk assessment, and monitoring of disease 
progression/treatment response.  Unlike TTE, CMR permits reliable, reproducible, and 
accurate morphologic and volumetric assessment of the RV with minimal operator 
dependence, no interference from adjacent bone or air, and no reliance upon geometric 
assumptions.  The mechanical properties and blood flow of the proximal pulmonary vessels 
can also be examined using velocity-encoded sequences, allowing comprehensive assessment 
of the heart and pulmonary circulation (cardiopulmonary unit) in a single sitting.  CMR is 
therefore a powerful tool for the non-invasive assessment of PVD and, while its use has thus 
far been restricted to the examination of PAH patients, its advantages make it an exciting 
potential tool for the detection of early PVD.   
 
CMR-derived measurement parameters of interest 
Initial remodelling of the RV is an adaptive response to an elevated afterload (AL) in the 
context of PVD, with hypertrophy serving to reduce wall tension (in accordance with the 
LaPlace law).  RV mass can be calculated with CMR by multiplying myocardial volume by 
specific gravity (1.05g/cm3), with superior reproducibility compared with TTE [52, 53].  In 
early stages of established PAH, RV mass correlates well with PAP [54] suggesting it may be 
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an early marker of PAH.  However, RV mass can increase as a normal physiologic response 
to physical activity in healthy subjects, making it difficult to differentiate between 
physiologic and pathologic adaptation in asymptomatic individuals.  Furthermore, like RV 
dilation and systolic dysfunction, RV hypertrophy is a relatively late phenomenon in the 
context of PVD, making it unsuitable for early disease detection. 
 
It is often considered a drawback of CMR that the TRV cannot be measured and used to 
estimate pulmonary pressures non-invasively.   However, unlike TTE, CMR allows the 
accurate and reliable measurement of blood flow velocity, blood volume, and blood vessel 
dynamics (e.g. pulsatility) via velocity-encoded phase-contrast cine CMR imaging (PC-
CMR) through the main pulmonary artery (PA), producing two sets of cine images: 
magnitude images that provide anatomic information and phase images in which velocity 
information is encoded.  Since the entire CO passes through the PA with each stroke before 
reaching the microvascular level where PVD predominates, PC-CMR at the PA level may 
provide ‘upstream’ insight to a ‘downstream’ vasculopathic disease.  Two promising CMR 
indices are proximal pulmonary vessel dynamics (or stiffness) and pulmonary arterial blood 
flow velocity. 
 
Proximal pulmonary vessel dynamics 
The pulmonary circulation receives the entire cardiac output with each stroke so that during 
stress (e.g. exercise), the pulmonary vessels must distend to accommodate increases in blood 
volume and flow.  The healthy pulmonary circulation is therefore a high compliance, low 
resistance system [55] that allows proximal vessels to buffer pulsatile flow and provide 
constant flow distribution downstream in an efficient manner.  The afterload (AL) – the 
hydraulic load imposed on the RV during ejection [55] - is traditionally measured in terms of 
Formatted: Left, Line spacing:  Double
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PVR, which describes the steady, resistive load (ratio of mean pressure to mean flow) only 
and neglects the pulsatile nature of blood flow.  Therefore, the compliance (change in volume 
for a given change in pressure) of the pulmonary vasculature, or its ability to dilate to accept 
pulsatile stroke volume, needs also to be considered when describing the total load on the 
RV.  This pulsatile component of RV AL has been shown to contribute approximately 25% 
of total AL in the pulmonary system in contrast to ~10% in the systemic system [56].  
 
Reduced global arterial compliance and increased local proximal pulmonary arterial stiffness 
have both been demonstrated in PAH, and have been shown to be predictors of mortality, 
response to vasoreactivity testing, and functional capacity as determined by 6MWD [57] [10, 
58-63].  Histological specimens demonstrate changes in elastic pulmonary arteries of PAH 
patients that are likely to directly affect vascular compliance, including an increased burden 
of fibrosis and atypical elastic patterns [64] [65].  Whether the increased stiffness is 
secondary to the elevated distending pressure alone, or pressure-independent changes of the 
vessel properties, is not yet fully elucidated [63].  However, there is mounting evidence 
implicating mechanical alterations in these vessels playing a pathophysiological role in 
disease progression, even in the early stages.  Given many of these measurements can be 
made non-invasively by CMR, they form an attractive target of interest for the detection and 
monitoring of PVD. 
 
The relationship between the resistive afterload (or resistance, R) and pulsatile afterload (or 
compliance, C) has been shown to be inverse and their product, the RC-time (describing the 
decay of PAP during diastole) the same in healthy individuals and patients with pulmonary 
hypertension (Figure 5) [66].  Lankhaar et al showed this relationship was maintained during 
therapy in patients with pre-capillary pulmonary hypertension, concluding that greater 
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haemodynamic improvement is achieved by a reduction in both R and C rather than R alone, 
which is a more common measure of treatment success [60].  This provides a plausible 
explanation for why patients with mild pulmonary hypertension (less severe R) often show 
greater clinical response to therapy than those with severe pulmonary hypertension (more 
severe R), despite a similar reduction in R [60, 67].  Furthermore, the inverse relationship 
between R and C highlights the importance of C on total RV afterload, implying that early in 
disease progression C may be compromised despite a normal R, which may explain why C is 





Figure 5: If the RC-time is constant, patients will always move along the curve so for a 
change in resistance R, there will also be a change in compliance C.  Patient A, with mild 
pulmonary hypertension (lower baseline R), will have a greater C for the same R than 
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patient B, with more severe pulmonary hypertension (higher baseline R).  Reprinted with 
permission, source [60]. 
 
Sanz et al assessed pulmonary arterial stiffness in 94 patients with known or suspected 
pulmonary hypertension using CMRI and same-day RHC data [63].  Three groups were 
identified based on RHC data: no pulmonary hypertension, exercise induced pulmonary 
hypertension (eiPH, mPAP >30mmHg with dynamic exercise), and pulmonary hypertension 
at rest (mPAP >25mmHg).  They found strong correlation between increased PA stiffness, 
increased pulmonary pressures, and high PVR.  This held true when adjusting for the 
distending pressure using stiffness index .  Interestingly, subjects with eiPH had lower 
arterial compliance and capacitance than those with no PH, despite similar resting 
haemodynamic profiles (mPAP, PVR etc.).  acknowledging the limitations here of defining 
eiPH by the absolute mPAP value rather than the mPAP/CO relationship, and the lack of 
longitudinal data regarding clinical outcomes of eiPH, these findings suggests that alterations 
in PA elasticity may occur before the development of a measureable PAP rise,  a notion 
supported by the RC-time curve  [43]  [60, 63].   
 
This hypothesis is also biologically plausible.   Stiffer proximal vessels can may directly 
contribute to disease progression by enhancing energy transmission to the distal vessels and 
microvasculature, altering shear stress and influencing endothelial cell function, 
vasoconstriction, smooth muscle cell proliferation and vascular remodelling [63, 68].  In 
addition to shear stress, stiffer proximal vessels can also affect downstream flow pulsatility.   
Li and colleagues recently looked at the specific effect of increased flow pulsatility caused by 
stiffer conduit vessels on a model of bovine pulmonary microvascular endothelial cells (ECs) 
[69].   High flow pulsatility, as compared to static or steady flow, significantly upregulated 
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gene expression for adhesion molecules and inflammatory cytokines implicated in PAH 
pathogenesis (e.g. ICAM-1, E-selectin, monocyte chemoattractant protein-1).  Functional 
upregulation was confirmed by demonstration of increased monocyte adhesion in pulse flow 
conditions.  
 
The effect of distal arterial EC dysfunction – caused by increased flow pulsatility - on smooth 
muscle cell (SMC) phenotypic changes has more recently been investigated using bovine 
pulmonary arterial co-culture (endothelial and smooth muscle cells, separated by a 
microporous membrane) [70].   In the presence of ECs, high pulsatility flow increased both 
SMC size and expression of the contractile proteins smooth muscle α-actin, and smooth 
muscle myosin heavy chain.  When ECs were absent from the culture, high pulsatility flow 
decreased the expression of both contractile proteins without influencing the size or number 
of SMCs.  Flow rate and shear stress were similar in the high pulsatility and control arms 
(steady flow and static flow), suggesting the pulsatile nature of the flow was responsible. 
Possible contributory EC-derived molecular signals were sought by analysing protein and/or 
mRNA expression.  Vasoconstrictors [angiotensin converting enzyme (ACE), and 
endothelin-1 (ET-1)], vasodilator [endothelial nitric oxide synthase (eNOS)], and growth 
factor [transforming growth factor – β (TGF-β)] levels in ECs were compared.  High 
pulsatility flow reduced eNOS, and increased ACE, TGF-β, and ET-1, which are frequently 
elevated in PAH patients.  Pharmacological antagonism of these signalling pathways 
prevented pulsatility-induced EC-mediated SMC changes.  Thus, a vicious cycle of 
remodelling can be proposed where proximal vascular stiffening augments downstream shear 
stress and pulsatility, promoting small vessel remodelling.  In turn PAP rises, increasing 
circumferential stress on proximal vessels with subsequent smooth muscle cell-meditated 
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wall thickening and higher vessel stiffness, promoting further downstream remodelling and 
so on [71, 72].  
 
These data suggests that non-invasive assessment of PA stiffness at rest may enable detection 
of early PVD.  Based on the RC-time curve, it may also be possible to monitor change in PA 
stiffness under different loading conditions (e.g. in response to a vasodilator stress), thereby 
unmasking abnormalities not readily evident at rest.  This is discussed later. 
 
 
Pulmonary arterial blood flow velocity 
Studies have identified CMR-derived parameters relating to mPAP [54, 63, 73-79] and PVR 
[80-83].  Recently Swift et al derived predicted mPAP from multivariate regression analyses 
of CMR measurements taken from 64 treatment-naïve patients with suspected pulmonary 
hypertension [84].  They went on to validate this in another 64 patients, as well as estimate 
surrogate measures of PAWP and CO.  Estimated pulmonary vascular resistance was 
calculated from these measurements.  A strong correlation between CMR-estimated mPAP 
and RHC-derived mPAP was found (R=0.67), and CMR could reliably identify a PVR 3 
Woods Units (area under ROC curve = 0.94, CI 0.88-0.99 p value <0.0001).  However, the 
statistical model for estimating mPAP is cumbersome and is not validated in treated patients 
or under different loading conditions, such as during vasoreactivity testing. 
 
A more straightforward PA flow parameter to measure from phase-encoded CMR images is 
the mean pulmonary arterial flow velocity (meanPAvel), which has been shown to strongly 
correlate with PVR and mPAP in an inverse logarithmic manner [78, 81-83].  Postulated 
contributing mechanisms to this inverse correlation include small vessel remodelling, 
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vasoconstriction, and in situ thrombosis slowing flow through these vessels; PA dilatation in 
the setting of chronic pressure overload; and RV systolic failure in more advanced disease 
[82].  By averaging the velocities through the entire cardiac cycle rather than just systole, as 
is measured by Doppler echocardiography, the assumption that flow is uniform during all 
phases is avoided [83].  In 2007, Sanz and colleagues sought to identify PA flow parameters 
obtained by phase-encoded MR that may allow non-invasive diagnosis of PH [78] and of the 
many flow parameters assessed, meanPAvel showed the strongest correlation with invasively 
acquired haemodynamic measurements, with correlation coefficients of -0.86, 0.76, and -0.73 
for PVRI, sPAP, and mPAP respectively.  These did not vary significantly among different 
subgroups of PH, although interpreting values in high output states (e.g. portopulmonary 
syndrome) was cautioned.   
 
Garcia-Alvarez et al showed meanPAvel to be the strongest univariate predictor of PVR in 
their derivation of a non-invasive estimation of PVR, and hence it carried the highest weight 
in that predictive model (Spearman correlation coefficient of -0.83 between meanPAvel and 
PVR) [82].   The relationship demonstrated between meanPAvel and PVR was curvilinear 
(Figure 6) and therefore at very high PVRs, meanPAvel may be a less accurate reflection of 
PVR [82].   Nevertheless, this shouldn’t preclude detecting changes over time, such as a 
reduction down to moderately elevated PVR levels – an important indicator of treatment 
response.  Indeed, the same laboratory went on to show that the change in MRI-derived 
parameters correlated with haemodynamic changes over time in PAH patients [81].  Patients 
with haemodynamic improvement had increased meanPAvel and reduced PA area, whilst 
those that did not improve had reduced meanPAvel and increased PA area.  Consequently, 
these CMR-derived parameters were found to have a good ability to identify haemodynamic 
improvement (area under receiver operating characteristic curve of 0.83, p= 0.014, for 
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meanPAvel; and 0.81, p=0.021, for PA area). Garcia-Alvarez et al also demonstrated the 
ability of PA velocity measurements to reflect changes in PVR over time, this time using a 
porcine model of PAH induced by microsphere embolization [83].  They estimated a 10% 
decrease in meanPAvel correlated with a 1 Wood unit rise in PVR.  Finally, the same 
laboratory showed a strong correlation between change in meanPAvel and change in PVR 
and mPAP during acute vasodilator testing with 100% oxygen in the same porcine model, 
suggesting this could be a method of non-invasively assessing vasoreactive response [83].  
 
 
Figure 6: Univariate association of PVR and meanPAvel.  Reprinted with permission, source 
[82]. 
 
‘Stressing’ the cardiopulmonary unit 
Like most stress tests, dynamic exercise assessment of the cardiopulmonary unit in the 
context of PVD is likely to provide pathophysiological insight not necessarily evident at rest.  
As discussed, widespread application is hindered by difficulty standardising the exercise 
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stress component and non-invasively measuring appropriate physiologic parameters and, 
while exercise testing during CMR is possible [85, 86], it is technically and logistically 
difficult and not widely available.  An alternative approach is to use a vasodilator agent as a 
stress modality, a practice commonly employed during diagnostic RHC of PAH patients 
(invasive vasoreactive challenge).  Adenosine is a readily available endogenous nucleoside 
analogue with potent vasodilator properties that has been used in PAH as a vasoreactive 
agent for over 20 years, and is an accepted agent for this purpose in current guidelines [40].  
Administered intravenously, it has selectivity for the pulmonary circulation given its rapid 
metabolism and short half-life [87].  Furthermore, its predominant effect of microcirulatory 
vasodilation does not require an intact endothelium [88, 89], and in higher primate models, 
no effect on conduit pulmonary vessel diameter has been found [90] [89].  Previous studies 
using adenosine in PAH have shown a significant reduction in PVR (33% - 39%) associated 
primarily with elevated cardiac output rather than reduced mPAP, and largely unchanged 
mean systemic arterial pressure [87, 91, 92].  These properties, its favourable safety profile, 
and its frequent use as a coronary hyperaemic agent both invasively and non-invasively make 
adenosine an attractive agent for use as a ‘stress’ agent in this population, particularly given 
the administered doses can be easily controlled and replicated [93].   
 
Rationale for the use of adenosine as a vasodilatory stress agent for the present protocol 
stems from pre-clinical and clinical studies addressing the prognostic relevance of invasive 
haemodynamic changes during vasoreactive challenge in established PAH, and the concept 
of pulmonary flow reserve (PFR), an analogous measure of pulmonary microciculatory 
compromise to coronary flow reserve (CFR), a commonly employed and well validated 
marker of coronary vascular integrity.  These concepts, and how they may be measured with 
CMR, will be discussed in the ensuing sections. 





Invasive pulmonary vasoreactivity in established PAH 
Patients with PAH are often challenged with a vasoreactive agent during diagnostic RHC to 
determine suitability for calcium channel block therapy.  The traditional ‘positive response’ is 
near normalisation of pulmonary pressures (decrease in mPAP by ≥10mmHg to ≤40mmHg) 
with an unchanged or increased CO [94].  Only ~10% of iPAH and APAH patients exhibit 
this ‘classic’ response, and approximately half of these show sustained clinical response to 
CCB therapy [95].  However, this challenge can also provide pathophysiological insight if 
considered on a continuum rather than as an all-or-nothing outcome, with larger 
improvements in haemodynamics possibly reflecting a phenotype with more vasoconstriction 
and less vascular remodelling [96].  Malhotra et al retrospectively assessed the utility of 
using the response to inhaled nitric oxide (NO) and oxygen to predict survival in 80 newly 
diagnosed PAH patients [97].  Median reduction in PVR was 30%, and median reduction in 
mPAP was 12% with inhaled NO/oxygen.  Baseline characteristics and haemodynamics of 
patients stratified above and below these median values were similar.  Dichotomised, those 
with ≥30% reduction in PVR had a 53% reduction in age-adjusted mortality, and those with 
≥12% reduction in mPAP had 55% reduction in mortality over a median follow up period of 
2.4 years.  This held true after adjusting for known multivariate predictors of survival, such 
as age and right atrial pressure (RAP).   
 
McLaughlin et al found the change in PVR with intravenous adenosine was a univariate 
predictor of survival in PAH patients going on to intravenous epoprostenol therapy [98].  In 
contrast, baseline mPAP and PVR did not predict survival.  A more significant PVR 
reduction (50%) in response to short-term prostacyclin challenge was also found to be a 
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univariate predictor of mortality in a retrospective study by Raffy et al [99].  Again, baseline 
haemodynamics were similar and unable to predict survival.  A recent retrospective analysis 
of iPAH patients diagnosed in a single centre in Korea showed that baseline vasoreactive 
response was a good predictor of survival, whereas baseline rest haemodynamics were not 
(only mPAP was significantly different between ‘responders’ and ‘non-responders’ at rest) 
[100]. 
 
This work highlights the potential utility of vasoreactive testing to not only identify the small 
number of patients that may benefit from CCB therapy, but also to aid in prognostication and 
patient management (e.g. more aggressive drug therapy or closer patient monitoring in ‘poor’ 
responders).  While the pathobiologic processes that govern vasoreactivity are incompletely 
understood [101], a rational hypothesis is that compared with resting measures, 
haemodynamic changes during  vasoreactivity challenge more accurately define 
vasculopathic burden and hence, cardiopulmonary reserve (NOTE: not considering those with 
a ‘true’ vasoreactive response and sustained therapeutic benefit with CCB therapy: these 
patients likely represent a distinct molecular pathophenotype [101]).  This approach has not 
been applied to the detection of early PVD, in part due a lack of non-invasive modality with 
which to measure response.  Changes in proximal pulmonary vessel dynamics and 
meanPAvel measured with CMR may provide such a method. 
 
Vasoreactive challenge and pulmonary vessel dynamics 
The relationship between vasoreactivity response, haemodynamic parameters, and intrinsic 
elastic PA properties has been investigated invasively using intravascular ultrasound (IVUS) 
of elastic pulmonary arteries (2-4mm) during RHC in patients with iPAH [102].  This study 
demonstrated that patients who vasodilated during epoprostenol infusion (vasoreactive agent) 
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as measured by IVUS (increase in diastolic area, dA 10%) had higher baseline IVUS 
pulsatility (IVUSp) and lower baseline elastic modulus (E).  This was despite similar resting 
mPAP and pulse pressure between both groups, implying the reduction of IVUSp and E were 
due to differences in intrinsic viscoelastic properties of the arteries rather than haemodynamic 
conditions.  However, there was no correlation between baseline arterial stiffness, vasodilator 
response (dA change) and vasoreactive response as measured by haemodynamic changes 
(mPAP, PVR).  Those that did vasodilate (IVUS dA 10%) had a stable mPAP but increased 
CI, capacitance, and stroke volume index, and therefore a reduced PVR [102].  This is in 
keeping with the RC-time constant discussed previously, and raises the possibility that 
assessing elastic arterial vessel properties (i.e. pulsatile afterload) during vasoreactive testing 
may improve identification of patients with less severe remodelling, more vasoconstriction 
and possibly improved response to vasodilator therapies on the basis that a ‘vasodilator 
patient’ may not be a ‘vasoreactive patient’ as assessed by currently recommended 
haemodynamic parameters.   
 
Local pulmonary artery mechanical properties have also been investigated before and after 
six months of bosentan therapy (an endothelin receptor antagonist) in a small number of PAH 
patients, again using IVUS and RHC data [103].  At baseline, PAH patients had thicker 
arterial walls (34% ± 2% vs. 17% ± 2%) despite similar luminal diameters, reduced 
compliance, reduced distensibility, higher elastic modulus and higher stiffness index β 
compared with age and sex matched controls.  The higher stiffness index β and elastic 
modulus implied altered intrinsic mechanical properties secondary to vascular remodelling, 
rather than simply a manifestation of the altered haemodynamic conditions.  Following 6 
months of bosentan therapy, RHC with IVUS did not show a change in any markers of 
pulmonary artery stiffness or wall thickness.  Ignoring the limited power of this study (N = 8 
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patients), this could be explained by the fact that severe PAH patients such as those included 
(average mPAP 48mmHg ± 3mmHg) operate on the flat and stable part of the 
distensibilty/mPAP curve (Figure 5), and since the RC-time constant remains the same during 
therapy, a relatively large reduction in PVR would be required to modify arterial compliance.  
Alternatively, it may be all 8 patients were ‘non-responders’ by traditional markers of 
treatment response (e.g. haemodynamic data or clinical indicators), although these data were 
not presented to confirm or refute this.  This raises the possibility that less severe PAH 
patients (lower baseline mPAP), or severe PAH patients that respond to therapy (e.g. 
increased functional capacity, reduced PVR) may show changes in pulmonary stiffness with 
therapy. The corollary is that pulmonary vessel stiffness precedes increased PAP and PVR, 
and therefore PAH-specific therapy may not affect pulmonary stiffness in advanced disease. 
 
An increase in proximal PA compliance, measureable by CMR, may therefore accompany a 
temporary reduction in the resistive AL (or PVR) induced by IV adenosine (leftward shift on 
the RC curve, Figure 5).  This may enable a more comprehensive assessment of the 
pulmonary vasculature than possible by resting measures (RHC or CMR-derived) alone, 
thereby facilitating detection of early PVD or, in established PAH, providing a novel means 
to monitor disease progression and treatment response longitudinally. 
 
The concept of pulmonary flow reserve and relationship to CMR-derived meanPAvel 
measured during vasoreactivity 
The concept of flow and haemodynamic assessment under different loading conditions is not 
new but there is a paucity of data relating to its application in the assessment of the 
pulmonary circulation.  Coronary flow reserve (CFR) is a validated measure of the functional 
status of the coronary circulation, and is derived by assessing Doppler flow velocity at rest 
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and with hyperaemia, often induced with adenosine [104].  It reflects the magnitude of the 
increase in coronary flow above baseline when maximal coronary vasodilation is present.  
Given most resistance to flow is microvascular in origin, in the absence of epicardial 
coronary artery stenoses, it is a marker of microvascular function.  Indeed, lower CFR values 
have been associated with increased cardiovascular events [105].  In the pulmonary 
circulation, the small arteries and arterioles are also a key site of resistance, since resistance is 
strongly related to vessel diameter [106].  
 
At present, there is no validated method to assess pulmonary microcirculatory function in 
humans.  Ilsar and colleagues used a higher primate model to investigate the feasibility of 
measuring the physiological index of ‘pulmonary flow reserve’ (PFR = maximal hyperaemic 
pulmonary blood flow/basal pulmonary blood flow) [90].  They used a Doppler sensor 
guidewire advanced into segmental level pulmonary arteries of ketamine-anaesthetised 
baboons.  Saline, papavarine and adenosine were infused at incremental doses into the 
pulmonary circulation and vessel diameter, flow velocity and haemodynamics were recorded 
pre- and post- infusion.  They found that measurement of PFR in this way was feasible and 
reproducible using either adenosine or papavarine (no change in Doppler velocity was seen 
with saline infusion).  Importantly, adenosine produced dose-dependent incremental 
hyperaemia that plateaued at 200mcg/kg/min, and there was no change in vessel diameter 
observed.  Therefore, they concluded that in vivo measurement of PFR may have a role in the 
assessment of pulmonary microcirculatory integrity. 
 
Ilsar et al went on to demonstrate that PFR could track cumulative microvascular obstruction 
in a baboon model [107].  Pulmonary flow reserve was again measured with a Doppler sensor 
guidewire using intrapulmonary adenosine infusion at a dose of 200mcg/kg/min to induce 
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hyperaemia.  Ceramic microspheres were then infused in increasing amounts (104, 105 and 
106 particles) into the catheterised pulmonary arterial segment.  Pulmonary flow reserve was 
re-calculated at each dose of microspheres and a progressive reduction in Doppler flow 
velocity with increasing particle administration was noted.  Resting Doppler velocity was not 
affected until the highest dose of ceramic microspheres, suggesting PFR is sensitive to 
microcirculatory changes of insufficient severity to affect resting flow.  However, 
generalizability of these findings is limited by the small sample size (3 baboons) and lack of 
validation of microsphere obliteration as a PAH model.   
 
The same laboratory conducted a similar study on 13 baboons, but instead used 
thermodilution-derived mean transit-time (Tmn) as a surrogate for pulmonary blood flow 
(instead of Doppler-derived flow velocity), allowing the calculation of both PFR and 
Pulmonary Index of Microcirculatory Resistance (PIMR = maximum hyperaemic distal 
pulmonary artery pressure x maximum hyperaemic Tmn) [107].  In the coronary circulation, 
the index of microcirculatory resistance (IMR = maximum hyperaemic distal coronary artery 
pressure x maximum hyperaemic Tmn) has been shown to be more reflective of true 
microcirculatory resistance than CFR, which also incorporates epicardial coronary artery 
integrity [108-110].  Using a similar protocol to previous studies, PFRthermo and PIMR were 
calculated at rest and with progressive microvascular obliteration induced by microsphere 
infusion.  Feasibility and reproducibility of both measurements were demonstrated.  In 
response to incremental microvascular obliteration, PAP remained unchanged but a 
progressive reduction in PFRthermo, and increase in PIMR was seen (see figure 7).  Again, this 
provides evidence that assessment of pulmonary microcirculatory integrity may provide a 
novel technique to identify pulmonary vascular disease before measureable PAP or PVR 







Figure 7: Cumulative microvascular obstruction induces progressive reductions in PFRthermo 
and increases in PIMR.   
Reprinted with permission, source [111], Fig. 2. 
 
While invasive PFR has not been validated in humans, resting pulmonary flow velocity 
waveforms have been studied using Doppler sensor guidewires [112].   These were advanced 
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into the distal segment of the left lower lobe pulmonary arteries of 7 treatment-naïve PAH 
patients, both before and after 6 months of PAH-specific therapy (bosentan).  Importantly, 
the waveforms obtained had excellent signal-noise ratio, implying a feasible technique.  
Treatment responders (n = 3) and non-responders (n = 4) were defined by the presence or 
absence of >40m increase in 6-minute walk distance and an improvement in functional class.  
Responders showed a large increase in average diastolic velocity as well as mean velocity of 
pulmonary blood flow over the 6-month period.  Presumably this reflected a reduction in 
distal vascular resistance, although haemodynamics were not reported.  Nevertheless, it does 
provide the basis for further study to investigate pulmonary blood flow assessment can 
provide insights into the pulmonary vasculature, and how this may assist with diagnosis, 
prognostication and monitoring of treatment response.  
 
Assessment of coronary microcirculatory integrity can be confounded by the presence of 
epicardial coronary artery stenosis.  In this setting, a low CFR as assessed by Doppler flow 
velocity can reflect epicardial coronary stenosis, microvascular dysfunction, or a combination 
of both.  The IMR, after collateral flow is considered, is more specific for coronary 
microvascular integrity as it is not impacted by epicardial stenosis [108].  In contrast, the 
pulmonary circulation receives the entire cardiac output with each stroke via the main 
pulmonary artery and, except for chronic thromboembolic pulmonary hypertension (CTEPH) 
with proximal thrombus, pulmonary flow is not impeded in pulmonary vascular disease until 
the proximal microcirculatory level where pathognomonic remodelling occurs.  Using 
intravenous adenosine as a hyperaemic agent and acknowledging that intravenous adenosine 
has been shown to preferentially vasodilate the pulmonary circulation over the systemic 
circulation (presumably due to the rapid metabolism limiting systemic drug delivery) [93, 
113]; CO is thought to increase as a direct result of reduced RV afterload rather than 
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enhanced inotropy [93, 114, 115]; pulmonary vascular disease in PAH is heterogeneous in 
anatomical location throughout the lungs [116, 117]; and the site of vasodilation is thought to 
be the proximal microcirculation where remodelling predominates [90, 111], it can be 
hypothesized that PFR measured by blood flow velocity (assuming unchanged vessel cross 
sectional area) at any point ‘upstream’ will reflect pulmonary microcirculatory integrity and 
the ability of the RV to augment flow in proportion to AL reduction.  Acknowledging the 
superior prognostic power of clinical and haemodynamic parameters that reflect functional 
reserve over those measured at rest, this should provide a more comprehensive assessment of 
the RV/pulmonary arterial system than resting parameters alone [118-120].  Furthermore, 
acknowledging that CMR-derived meanPAvel correlated strongly with change in PVR and 
mPAP during acute vasodilator testing in a pre-clinical study, this may be a feasible 
parameter with which to quantify the vasoreactive response and pulmonary blood flow 
changes non-invasively in humans [83].  
 
1.2.4 RISK ASSESSMENT IN ESTABLISHED PAH 
 
Periodic longitudinal evaluation of PAH patients to assess severity, prognosis, and treatment 
response is recommended by current guidelines [7].  Since no single investigation is 
sufficiently instructive, the recommended approach is multidimensional incorporating 
clinical, echocardiographic, exercise, haemodynamic, and biomarker assessments (Figure 8).  
Risk stratification, based on estimated 1-year mortality (low risk <5%; intermediate risk 5-
10%, high risk >10%), is applicable at the time of diagnosis as well as during follow-up, with 
low risk criteria functioning as treatment goals.  There are limitations to this approach: many 
cut-offs are based on low level evidence and expert opinion; it is resource intensive; and, 
prognostic relevance of these parameters at follow-up are less well understood, as are their 
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changes longitudinally.  A unified approach would simplify patient management and 
therapeutic decision-making. 
 
Figure 8: Risk assessment in PAH.   
Reprinted with permission, source [7]. 
 
Since PAH is, by definition, a haemodynamic condition, it is not surprising that the 
prognostic relevance of invasive haemodynamic parameters have received most attention.  
Haemodynamic markers of RV function at baseline – right atrial pressure, cardiac index and 
cardiac output - have been shown to be predictors of survival [14, 121].   Pulmonary vascular 
resistance and mPAP have also been shown to be baseline prognostic indicators [121, 122], 
although mPAP can decline in advanced disease with RV dysfunction and, therefore, 
variables that directly reflect RV function generally have superior predictive value [40].  
 
Non-randomised studies have reported associations between longitudinal haemodynamic 
changes and clinical events (65, [98, 123-125]. Improvements in cardiac index have predicted 
prognosis, emphasising the importance of RV function and adaptation on survival [98, 124, 
126].  A reduction in PVR at different time points after treatment initiation has also been 
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associated with better survival independent of the therapy instituted [98, 123-125].  A 
retrospective analysis of 122 PAH patients with repeat RHC 3-4 months after treatment 
initiation addressed the long term predictive value of early changes in haemodynamic 
parameters [127].   An increase in CO of 0.22L/min was associated with a significantly 
worse transplant-free survival over a mean follow up time of 4.7 years, with a hazard ratio of 
2.05 (CI 1.15-3.67, p value 0.015).   A larger reduction in PVR was also a predictor of better 
transplant-free survival.  Dichotomised into higher and lower PVR reductions, the latter 
group had an adjusted HR of 1.89 (CI 1.02-3.51, p value 0.044) for transplant or death (HR 
adjusted for date of diagnosis, diagnostic class, age and gender).  The same was not seen for 
changes in mPAP, with an adjusted HR for those dichotomised to a lower reduction group of 
1.12 (CI 0.63-1.97, p value 0.704) for transplant or death.   
 
A more recent meta-analysis investigated the relationship between haemodynamic changes 
and clinical events (all-cause death, hospitalisation for PAH, lung-heart transplant or 
initiation of rescue PAH therapy) based on data from randomised clinical trials [128].  
Sixteen randomised trials were included with a total of 2353 patients.  They demonstrated 
that pharmacological treatment was associated with a significant reduction in clinical events. 
A significant inverse correlation was found between change in 6MWD and change in PVR 
and CI.  However, no relationship was found between the change in haemodynamic 
parameters (PVR, PAP, CI and RAP) and clinical events when analysed as a composite or 
individually.  It should be noted however that follow-up duration in these trials was short 




Venetuolo et al undertook a patient-level pooled analysis of four therapeutic, randomised 
placebo-controlled trials to explore whether changes in haemodynamics measured 12-weeks 
after treatment initiation accounted for differences in clinical events (death, lung 
transplantation, hospitalisation for PAH, atrial septostomy, escalation of PAH therapy or 
withdrawal due to clinical worsening) [129].  Like the findings of Savarese et al, this analysis 
of 1119 patients found that treatment significantly reduced the odds of a clinical event and 
lowered RAP, PVR and mPAP, and increased CI.  A decrease in PVR and an increase in 
CO/CI were associated with a significant reduction in the odds of a clinical event, while no 
such association was evident with change in mPAP or PA compliance.  They went on to 
quantify the proportion of the treatment effect (reduction in clinical events) attributable to 
haemodynamic changes.  At most, they found a change in CI and PVR accounted for 11.7-
13.9% of the impact of treatment on event rates, and they were therefore unable to conclude 
that haemodynamic changes over short-term treatment periods could act as surrogate markers 
for clinical events.  Acknowledging that these findings pertain to short-term follow-up 
periods only, the authors postulated that therapy may act on organ systems other than the 
pulmonary circulation to confer benefit.   
 
Alternatively, treatment may alter RV loading conditions in a more complex manner than is 
assessable by rest haemodynamics alone, as suggested by Castelain et al [45].  Moreover, 
unrelated systemic processes such as anxiety, hypertension, and sedation may influence 
hmodynamic measures made at rest, and a single PVR measurement in PAH patients may be 
misleading due to the fact that the zero-flow intercept of a pressure-flow plot is positive and, 
therefore, the PVR is no longer a constant independent of the absolute blood flow and mPAP 
[45].  A more reliable assessment of the functional state of the pulmonary circulation may be 
achieved by examining the slope reflecting the multipoint relationship between CO and 
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mPAP (‘true PVR’) taken during incremental exercise [10, 45, 130].  To date no prospective 
therapeutic studies have incorporated the assessment of pulmonary haemodynamics under 
different loading conditions (e.g. graded exercise, repeat vasoreactivity challenge) over time 
with clinical event data other than exercise tolerance [45, 130].  The hypothesis that dynamic 
changes in pulmonary haemodynamics - or appropriate non-invasive surrogates - assessed 
under different loading conditions (i.e. ‘stress’) over time will provide more insightful 
prognostic data warrants further study.  Acknowledging the prognostic relevance of 
haemodynamic changes during diagnostic vasoreactive challenge, and the prospect of 
measuring these changes with CMR-derived surrogates (proximal pulmonary vessel 
dynamics and meanPAvel), a standardized, non-invasive pulmonary vasoreactivity protocol 
using IV adenosine as the stress agent may afford such a means. 
 
Cardiac magnetic resonance imaging meets many of the primary requirements for an ideal 
tool to monitor PAH patients: reproducible assessment of RV size and function, minimal 
observer and operator dependence, standardized, non-invasive, ‘patient-friendly’, time-
efficient, and capable of providing prognostically relevant information at baseline and during 
follow-up.  Regarding the latter, there is accumulating data supporting the prognostic value of 
the longitudinal change in several CMR-derived indices in established, treated PAH patients 
[131].  Van de Veeronk and colleagues found RV ejection fraction (RVEF) was a stronger 
baseline predictor of survival than PVR, and change in RVEF was independently related to 
mortality whereas change in PVR was not, highlighting the importance of monitoring RV 
function [132].  Low stroke volume (SV) at baseline has been linked to poor survival, as has 
a lack of improvement in SV with PAH treatment, with change in SV also linked to exercise 
capacity as determined by 6-minute walk distance (6MWD) [133, 134].  The authors also 
noted a stronger link between survival and change in SV than change in cardiac index (CI), 
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presumably due to heart rate (HR) compensation [133], and calculated a minimal important 
difference in indexed SV of 10 ml at follow-up which correlated with a clinically relevant 
rise in 6MWD over the same period [134].   
 
Right and left ventricular volumes have also been shown to independently predict survival at 
baseline, and progressive dilation of the RV and contraction of the LV over time has been 
related to functional decline and early mortality [133, 135].  A recent systematic review and 
meta-analysis addressing prognostic CMR parameters in PAH confirmed a rise in RV end 
diastolic volume (RVEDV) and RV end systolic volume (RVESV), as well as a decline in 
LV end diastolic volume (LVESV), predicted an adverse prognosis [136].  These findings 
highlight the inexorable link between the left and right heart chambers whereby maladaptive 
remodelling and systolic dysfunction of the pressure-loaded RV impacts LV geometry and 
filling, primarily via septal shift [137].   
 
Change in RV mass does not seem to be closely linked to survival [133, 135].  Since 
correlation between PAP and RV mass has been demonstrated in mild PH [54], RV 
hypertrophy is likely an adaptive response to a pressure load.  With further disease 
progression, RV dilation outstrips compensatory hypertrophy, explaining its poor prognostic 
relevance as a follow-up marker.  
 
Less data exists regarding the prognostic value of change in proximal pulmonary vessel 
dynamics (i.e. PA stiffness) with therapy in established PAH.  As already noted, low 
pulmonary vascular distensibility may be an early marker of PVD and has, as such, been 
linked to an adverse prognosis at baseline in established PAH [59, 61, 138].  Change in 
meanPAvel has not been evaluated in this context.  Moreover, there is paucity of data 
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regarding CMR-derived indices measured during physiological stress, and no apparent 
studies evaluating change in such indices or their relationship to PAH prognosis, which may 
stem from limited capabilities of CMR centres to marry exercise stress and CMR.  Forouzan 
et al reported the feasibility of performing supine exercise during CMR in 21 healthy 
subjects, demonstrating a rise in PA stiffness (determined using the flow area method to 
measure pulse wave velocity, a marker of PA stiffness) with incremental exercise load 
although no change in relative area change of the main PA (RAC, maximum cross-sectional 
area - minimum cross-sectional area/max cross-sectional area) was found [85].  The authors 
concluded that the protocol great potential in clinical practice to non-invasively assess the 
pulmonary vasculature.    
 
As CMR protocols become more standardised and the associated costs decline, CMR is likely 
to becomes routine in the evaluation of established PAH.  The capacity to study the 
pulmonary vasculature, RV, and their interaction in a single sitting is enticing.  Furthermore, 
accessing the inherent benefits associated with physiologic stress may improve the yield of 
longitudinal evaluation significantly, and will be evaluated in the present body of work. 
 
1.2.5 THE RIGHT VENTRICLE AND CORONARY BLOOD 
SUPPLY/DEMAND 
 
Under normal loading conditions, early pre-clinical studies demonstrated that cardiac output 
(CO) and venous pressures were largely unaffected when the RV was rendered non-
functional by cauterization or occlusion of the right coronary artery (RCA) [139-141], 
implying a conduit rather than contractile role.   Pre-dating this work, Fineberg and Wiggers 
proposed that “circulatory failure following obstruction of the pulmonary circuit had no other 
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cause than fatigue of the right ventricle” [142].  While progress has been made to elucidate 
the mechanisms of RV fatigue in the context of an elevated AL, this has not translated to 
clinical treatments targeting the RV specifically, as has occurred in LV systolic dysfunction.  
Early pre-clinical work identified an increasingly important link between right coronary 
artery blood supply and cardiac performance with rising RV AL, although this relationship in 
is not well described in humans.   
 
Adaptive and maladaptive RV remodelling  
Right ventricular geometry is complex, consisting of inflow (sinus) and outflow (conus) 
tracts separated by the membranous interventricular septum.  Both the free wall and 
interventricular septum are convex (under normal loading conditions), so that and the RV 
appears crescentic in shape in cross-section.  Contraction is comprised of three patterns of 
myocardial deformation: inward or ‘bellowing’, circumferential, and longitudinal shortening, 
with longitudinal shortening contributing most to overall contractile performance [143].   The 
RV free wall is thin relative to the left ventricle (LV) because it uses only ~ 25% of the stroke 
work to pump the same stroke volume into the low resistance pulmonary circulation [144]. In 
the face of an elevated afterload, the RV must adapt to maintain forward flow and it is this 
capacity which primarily dictates prognosis in PAH.  [14, 121, 122, 145].  Adaptation 
involves myocardial hypertrophy and increased contractility in the early stages but with PVD 
progression, adaptive responses become insufficient to overcome AL leading to chamber 
dilatation as a means to maintain preload and cardiac output.  The interventricular septum 
flattens, reducing LV filling and stroke volume, although the ejection fraction is usually 
preserved  [146].  In late stages, RV wall stress is increased as dilatation is incompletely 
matched by hypertrophy (law of Laplace).   These changes are associated with an increased 
oxygen requirement.   
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Right ventricular remodelling associated with impaired systolic and diastolic function has 
been termed ‘maladaptive’, and predominates in PAH that is idiopathic in origin or secondary 
to connective tissue diseases.  In contrast, RV remodelling can be associated with preserved 
RV function, and is characterised by a less dilated, more hypertrophied RV.  This is termed 
‘adaptive’, and can be present in PAH secondary to certain congenital heart defects (Figure 9) 
[147].  The complex pathobiology driving maladaptive remodelling of the pressure-
overloaded RV is gradually being elucidated, but much remains unknown.  At a cellular 
level, thick filament protein myosin heavy chain (MHC) undergoes subunit α – to β-isotype 
switch, which can impact deleteriously on systolic function of the RV [148, 149].  Myocyte 
thin filament changes are also seen in the stressed RV, with increased expression of α-
skeletal actin and α-smooth muscle actin, and reduced expression of α-cardiac actin, although 
the impact on systolic function of these changes is not clear [149].  Proteins involved with 
regulating contractility, such as troponin and tropomyosin, are also implicated in the 
pathobiology of maladaptive remodelling, although most knowledge in this area is derived 
from scientific interest in left ventricular systolic dysfunction in left-sided heart failure.  Left-
sided models have also shown altered enzymes and ion channels directly involved with 
excitation-contraction coupling, depletion of adenosine triphosphate and other fuel sources, 
and a shift to glycolysis from fatty acid oxidation [149, 150].  Whether these events occur in 
the failing RV is unknown at this stage, although the metabolic shift to glycolysis is well 






Figure 9: Pathophysiology of RV remodelling in PAH.   
Reprinted with permission, source Vonk-Noordegraaf et al., JACC Vol. 62, No. 25, Suppl D, 2013. 
 
The extracellular matrix (ECM) is also implicated in maladaptive remodelling.   Increased 
fibrosis has been demonstrated in myocardial biopsies of PAH patients, and experimental 
models have shown increased collagen content linked to TGF-β signalling, and excessive 
activity of matrix metalloproteinases (MMPs) [151, 152].  Fibrosis may be partly caused by 
RV ischaemia and the inability of the microcirculation to adapt to the hypertrophic response 
(e.g. inadequate capillarization) [153].  An inflammatory contribution has been postulated, 
with an increased density of mast cells and neutrophils observed in pressure-loaded RV 
histopathological specimens obtained from human and animal-model studies [154, 155].  
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Paracrine signalling from these cells may contribute to driving ECM degradation and scar 
deposition, thereby promoting ventricular dilatation and impaired compliance [78, 152, 156].  
Interestingly, fibrosis in the pressure-loaded RV seems to occur less extensively than in the 
pressure-loaded LV (e.g. aortic stenosis, hypertension) [78, 156, 157], possibly explaining 
successful recovery of RV systolic function after lung transplantation for PAH, even when it 
is severely compromised at the time of transplant [158-160].   
 
Modifying these pressure-related changes are various neurohormonal, oxidative, nitrosative, 
ischaemic, and apoptotic influences and adaptations.  The renin-angiotensin system, 
adrenergic system, and natriuretic peptides are upregulated, with end-stage mediators (e.g. 
angiotensin II, aldosterone, and natriuretic peptides) reaching the RV via the systemic 
circulation.  Local cardiac cells, such as myocytes, endothelial cells, and fibroblasts, are also 
capable of secreting neurohormones in a paracrine fashion.  Via receptor tyrosine kinases 
(TKRs) and G protein-coupled receptors GPCRs), they affect cardiomyocyte growth, 
proliferation, and survival [149]. In PAH, the net result in the RV is myocyte hibernation, 
contractile dysfunction, and growth arrest, which contrasts sharply with that in the pulmonary 
vascular bed where resistance to apoptosis, excess cell division, and vasoconstriction 
predominate [161]. 
 
Certain neurohormones can increase production of reactive oxidative species (ROS) and 
reactive nitrogen species (RNS) via diverse mechanisms such as NAD(P)H oxidases, 
xanthine oxidase, cytochrome P450, and autooxidation of catecholamines [162].  Uncoupling 
of endothelial nitric oxide synthase (eNOS) can reduce available nitric oxide (NO) and 
increase superoxides, contributing to the imbalance between ROS and antioxidants - so called 
oxidative stress [163].  Oxidants can cause direct cellular damage via oxidation of molecules 
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such as lipids (lipid peroxidation) and DNA, and can promote contractile dysfunction by 
influencing enzymes involved in excitation-contraction coupling [149, 162].  They can also 
alter transcription factors such as nuclear factor-κB (NF- κB) or hypoxia-inducible factor-1 
(HIF-1), with a range of downstream effects [162].  The milieu established by oxidative 
imbalance favours adverse myocardial remodelling with inactivation and induction of cell 
damage, inflammation, and apoptosis. 
 
Relationship between RV afterload, myocardial coronary perfusion, and RV performance 
Unique physiology dictates that RV pressurization impacts both myocardial coronary blood 
supply (reducing the pressure index, PI: difference between aortic and RV pressures 
throughout the cardiac cycle) and ‘demand’ (increasing wall tension which can be 
approximated by the tension time index, TTI: area under the RV pressure curve in systole).  
Autoregulation of the coronary bed and enhanced myocardial oxygen extraction may 
compensate but following maximal vasodilation, blood flow becomes solely dependent on 
forward pressure and, therefore, imminently susceptible to further perturbations in the 
supply:demand balance (e.g. exercise, tachycardia, progression of PVD).  In this context, 
coronary blood supply may be insufficient to maintain energy-dependent cellular processes 
(particularly during physiologic stress such as exercise), leading to downregulation of 
contractility to restore the metabolic balance (‘perfusion:contraction matching’) [164].  It can 
be postulated therefore that RV ischemia may contribute to an impaired physiologic reserve 
and RV failure in PAH. 
 
 
Early pre-clinical work first shed light on these important relationships by demonstrating: 
increasing RV AL caused subendocardial ischemia in the presence of a patent right coronary 
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artery (RCA); occlusion of the RCA had negligible impact on overall cardiac performance 
under control conditions, but promoted more significant RV dysfunction when AL was 
elevated; RV performance could be restored by increasing RV blood supply, even when AL 
remained high; and, the ratio between RCA driving pressure (pressure index (PI): area under 
RV systolic curve) and RV oxygen demand (tension time index (TTI): area under RV 
pressure curve during systole) decreased as RV AL was elevated in a step-wise fashion, and 
that at very high loads, hyperemic coronary flow reserve was disappeared [140, 165-167] 
[168].  Together, these studies suggest that right coronary flow is increasingly important as 
the RV becomes stressed in systole and RV ischemia may underlie the transition from RV 
adaptation to failure. 
 
Considering the compelling pre-clinical findings, there is a surprising lack of clinical studies 
exploring relationships between RV AL, coronary status, and remodelling/performance, 
perhaps due to an inability to directly manipulate physiologic parameters to establish cause 
and effect.  Van Wolferen et al assessed RCA and left anterior descending (LAD) flow using 
CMR in subjects with PAH and chronic thromboembolic pulmonary hypertension (CTEPH), 
comparing flow profiles with healthy controls [169]. In the LAD, flow profiles were similar 
between control and PH groups, whereas the systolic-to-diastolic flow ratio in the RCA was 
significantly lower in the PH group (0.39  0.28 compared with 0.82  0.43, P = 0.007).  
Strong inverse correlations were found between RCA systolic-to-diastolic flow ratio and RV 
systolic pressure (R = -0.83 P <0.001), and total mean coronary blood flow per gram 
myocardial tissue and RV hypertrophy (R = -0.73 P < 0.001), leading the authors to propose 
that RV systolic stress due to PH caused systolic compression of epicardial RCA flow.   
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Gomez et al observed scintigraphic evidence of subendocardial RV ischemia in a subset of 
patients with severe PAH.   Presence of ischemia was associated with haemodynamic 
markers of RV dysfunction, including higher right ventricular end diastolic pressure 
(RVEDP; p < 0.001), higher right atrial pressure (RAP; p < 0.037) and lower mixed venous 
oxygen saturation (p < 0.0001) [170].  Biventricular myocardial perfusion reserve indexes 
(MPRIs), calculated using adenosine perfusion CMR, were found to be lower in scleroderma-
related PAH patients than scleroderma patients without PAH and healthy controls, suggesting 
impaired vasoreactivity or reduced coronary perfusion secondary to PAH in the scleroderma-
PAH group [171].  This correlated closely with markers of RV workload and dysfunction, 
suggesting ischaemia may contribute to functional decline.  Interestingly, LV MPRI was 
lower in the scleroderma PAH group than the scleroderma without PAH group, suggesting 
either the PAH itself, or more advanced scleroderma-related microvascular dysfunction, was 
the cause.  Peripheral endothelial dysfunction has also been shown in PAH patients [172, 
173], and has been correlated with pulmonary vasoreactive response to inhaled iloprost [173].  
This raises the possibility that coronary microcirculatory dysfunction in PAH could 
contribute to lower MPRI, rather than haemodynamic alterations per se being the sole culprit 
(e.g. compression of coronary circulation in setting of increased wall stress, or reduced 
coronary driving pressure in the setting of systemic hypotension).          
 
Calculating MPRI, particularly for the usually thin-walled RV, can be technically difficult, 
leading to interobserver variability [171].  Coronary sinus flow, which represents 
approximately 96% of total coronary efflux [174], can be measured via PC-CMR and 
incorporated with myocardial mass measurements to give myocardial blood flow per gram of 
myocardium [175].  Repeating these measurements with drug-induced hyperaemia permits 
calculation of coronary sinus flow reserve (CSFR), which has good correlation with the gold 
 58 
standard measure of coronary flow reserve, positron emission tomography (PET) [176, 177].  
Skrok et al found that mean CSFR was lower in PAH patients compared with healthy 
controls and the degree of impairment related directly to haemodynamic and CMR-derived 
measures of PAH severity and RV dysfunction, supporting a possible causative link between 
high RV AL, RV ischaemia, and RV dysfunction [178]. 
 
Clinical studies utilizing positron emission tomography (PET) have confirmed higher RV 
myocardial oxygen consumption (MVO2) at rest in PAH patients compared with controls, 
which was attributed to increased RV power output (to overcome elevated AL) and RV 
mechanical inefficiency [179, 180].  A high RV oxygen extraction fraction (OEF) was noted 
in their iPAH cohort at rest (69% ± 17%, which is comparable to the accepted normal LV 
OEF of 60-80% and considerably higher than the expected normal RV OEF, estimated 
between 45-50%) [181, 182] [180, 183, 184], suggesting diminution of the OEF reserve and a 
greater dependence on perfusion for myocyte oxygen delivery.  Not surprisingly therefore, 
Dubiel et al found that myocardial blood flow was higher (due to lower coronary vascular 
resistance) in the RV of patients with moderate PH (mPAP 31-60mmHg) [185].  Thus, even 
at rest, a moderately stressed RV has partially surrendered both OEF and perfusion reserves.  
Under severe stress (higher RV AL), Dubiel et al noted a failure to further augment resting 
blood flow (consistent with clinical studies utilising CMR-derived MPRI and CSFR), despite 
the commensurate rise in oxygen demand (greater RV power requirement).  Therefore, 
during progression from moderate-severe PAH, there appears a disproportionate imbalance 
between increasing RV oxygen demand and declining OEF/perfusion reserves, raising the 
risk of myocyte hypoxia, particularly during physiologic stress.  Moreover, this may be 
compounded by myocyte hypertrophy that is incompletely matched by neo-capillarization - 
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as has been observed in the RV of deceased, severe PAH patients – as flow per unit of 
myocardial mass decreases [153]. 
 
Measurement and manipulation of parameters that determine RV coronary status (supply and 
demand) may therefore be of considerable clinical use.    In a canine model, Buckberg and 
associates showed that an index reflecting the ratio of LV myocardial oxygen supply (area 
between diastolic aortic and LV pressure, DPTI) and ‘demand’ (area under LV systolic 
pressure curve, SPTI) calculated from routine invasive parameters could predict 
subendocardial ischaemia [186].  This was confirmed in humans, with a DPTI/SPTI <0.45 
predicting ischemic electrocardiogram (ECG) changes during strenuous exercise [187].  An 
analogous index of myocardial oxygen supply:demand for the RV was proposed by Cross 
[166]. Since the RV receives RCA flow during systole and diastole, the right coronary 
driving pressure or ‘supply’ (termed the pressure index, PI) was proposed as the area 
reflecting the aortic–RV pressure difference throughout the cardiac cycle while ‘demand’ 
(termed the tension time index, TTI) was estimated as the area under the RV systolic pressure 
curve.  Using canine models, Fixler et al showed the PI/TTI decreased in proportion to the 
degree of RV pressure overload and that under severe stress, hyperaemic coronary flow 
reserve disappeared [168].  Later work showed preferential subendocardial ischemia in 
response to acute RV pressure loading, with a decrease in the endocardial:epicardial PI/TTI 
with increasing load [165, 188].  Finally, in an experimental pulmonic stenosis model of RV 
systolic hypertension, compensated RV function transitioned to RV failure in response to the 




Despite these pre-clinical data and the attractive simplicity of the PI/TTI measurement, there 
are no apparent published reports exploring relationships between RV AL, PI/TTI, 
hyperaemic coronary flow reserve, and RV performance in humans.  Furthermore, 
relationships between RV micro- and macro-vascular coronary status and cardiopulmonary 
reserve in the context of PVD/PAH are unclear. Since PVD is progressive despite 
contemporary treatments and lung transplantation is neither universally available nor suitable, 
directly targeting determinants of RV oxygen supply, demand, and utilization may provide 




Pulmonary arterial hypertension is a rare clinical condition with an unacceptably poor 
prognosis despite the availability of effective but non-curative medical therapies.  While first 
and foremost a pulmonary vasculopathy, characterized by obliterative remodelling at the 
proximal microcirulatory level, diagnosis is contingent upon sequelae that only arise once 
vascular lesions are fully developed and the pulmonary vascular bed is considerably 
compromised (that is, pre-capillary pulmonary hypertension).  No validated method exists to 
detect pulmonary vascular disease during its initial stages, which may be an opportune time 
to initiate therapy.  Exercise haemodynamic stress testing of the cardiopulmonary unit - with 
the intention of unmasking a depleted reserve - is pathophysiologically attractive, but limited 
by technical and methodological concerns which are compounded by non-invasive 
measurement techniques (e.g. Doppler echocardiography).  Surrogate markers of pulmonary 
haemodynamics, accurate and reproducible indices of right ventricular structure and function, 
and proximal pulmonary vessel dynamics can all be reliably obtained without ionizing 
radiation during a single cardiac magnetic resonance imaging scan.  Stressing the 
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cardiopulmonary using intravenous adenosine and monitoring changes in CMR-derived 
indices may afford an alternative, novel approach to detecting a depleted reserve.  Following 
on, this may also provide a unified means to longitudinally monitor treatment response and 
disease progression in established PAH.  Finally, pre-clinical and clinical studies suggest that 
an imbalance between RV myocardial oxygen supply and demand may contribute to RV 
pump failure, the primary cause of premature mortality in PAH, although our understanding 
of the relationships between severity of pulmonary vascular disease, RV coronary perfusion, 
























The purpose of the present study is to design and assess feasibility, safety and tolerability of a 
non-invasive methodology to quantify pulmonary vasoreactive response in subjects with 
known or suspected PAH, and proceed to explore whether this methodology may afford a 
means to detect early pulmonary vascular disease and/or provide prognostic information (at 
baseline and longitudinally over time).  Since this is a single-centre study employing a novel 
approach to the interrogation of the cardiopulmonary unit in the context of PVD, it is 
important to clearly outline and justify the protocol design (for the purposes of, for example, 
external validation).   While methodology will also be covered in the results chapters 
(Chapters 3-5), this chapter will detail the CMR and RHC protocols in full, and rationalize 

















Figure 1: Study overview for participants with known or suspected PAH.  Age and sex 
matched healthy volunteers will undergo a single CMR with intravenous adenosine using the 






RIGHT HEART CATHETER PROTOCOL 
1. Patient preparation: 
a. No caffeine for 24 hours prior. 
b. Clear fluids only for 4 hours prior. 
c. Insert two 18-21 G peripheral intravenous cannulae (antecubital fossae). 
2. In the catheterization laboratory: 
a. No supplemental oxygen.   
b. Sedation at the discretion of proceduralist (intravenous midazolam and/or 
fentanyl).   
3. Right femoral venous access.  7 French sheath. 
4. 7 French Swan-Ganz thermodilution pulmonary artery catheter (Edwards 
Lifesciences, California, USA). 
5. Zero and fix transducer at level of mid-thorax. 
6. Resting pulmonary haemodynamic assessment (waveforms to be recorded for offline 
anaylsis): 
a. Right atrial pressure. 
b. Right ventricular pressure. 
c. Pulmonary artery pressure. 
d. Pulmonary arterial wedge pressure: catheter tip in zone 3 lung regions. 
Confirm by waveform visualization and oxygen saturation. 
e. Cardiac output by thermodilution (triplicate). 
7. Saturation run at discretion of proceduralist (recommended if a new case). 
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8. If resting mPAWP <15mmHg, proceed to vasoreactive challenge with intravenous 
adenosine: 
a. Start at 70mcg/kg/min infusion via peripheral line. 
i. After 2 minutes: Repeat measurement of pulmonary artery pressure, 
PAWP (do not confirm with SaO2), CO by thermodilution in triplicate. 
ii. Repeat arm-cuff systemic blood pressure. 
b. Increase infusion rate to 140mcg/kg/min. 
i. After 2 minutes: Repeat measurement of pulmonary artery pressure, 
PAWP (do not confirm with SaO2), CO by thermodilution in triplicate. 
ii. Repeat arm-cuff systemic blood pressure. 
c. Increase infusion rate to 210mcg/kg/min. 
i. After 2 minutes: Repeat measurement of pulmonary artery pressure, 
PAWP (do not confirm with SaO2), CO by thermodilution in triplicate. 
ii. Repeat arm-cuff systemic blood pressure. 
d. Cease infusion. 
9. Perform diagnostic coronary angiography via femoral or radial arterial access IF not 
performed in the preceding 3 years. 
10. Recorded waveforms to be directly visualized offline to ensure uniform 
haemodynamic measurements: 
a. Sinus rhythm: mean of 3 end-expiratory pressure measurements. 
b. Atrial fibrillation: mean of 7 end-expiratory pressure measurements. 





CARDIAC MAGNETIC RESONANCE IMAGING PROTOCOL 
Cardiac magnetic resonance imaging will be performed with a 1.5 T magnet (Magnetom, 
Siemens, Erlangen, Germany) according to the protocol shown in Figure 2.   
 
Figure 2:  CMR protocol (left) and purpose of chosen sequences (right). 
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INTRAVENOUS ADENOSINE DOSING 
The recommended regimen for intravenous adenosine infusion for invasive pulmonary 
vasodreactive testing is to start at 50mcg/kg/min and increase in 50mcg/kg/min increments 
every 2 minutes to a maximum dose of 350mcg/kg/min, unless limited earlier by side effects 
[40].  Two of the largest trials employing IV adenosine for this purpose postdate these 
guidelines.  They found a dose range of 50mcg/kg/min-200mcg/kg/min adequate for 
assessment of vasoreactivity, with higher doses increasing side effects without additional 
benefit [113, 190]. Furthermore, the doses causing maximal reduction in mPAP were much 
lower than expected (88 ± 40 mcg/kg/min and 78 ± 23 mcg/kg/min), suggesting 
recommended doses are too high.  In the coronary circulation, maximal hyperaemia may not 
be achieved at the commonly used dose of 140mcg/kg/min in a small proportion of subjects, 
but is very rare at a dose of 210mcg/kg/min, even in the setting of recent caffeine intake 
[191-193].    
 
Intravenous adenosine can cause transient chest tightness, dyspnoea, palpitations, facial 
flushing, and mild reductions in systemic arterial pressure [194] which abate quickly upon 
cessation, given its short half-life (~10 seconds) [195].  Stimulation of adenosine receptors in 
the atrioventricular node and bronchial smooth muscle can promote bradycardia and 
bronchospasm respectively, which are rarely clinically significant unless there are 
predisposing co-morbidities.   Overall tolerability and safety of adenosine perfusion CMR 
(for assessment of ventricular ischaemia) is acceptable at doses of 140mcg/kg/min and 
210mcg/kg/min [191, 193].  Bortaso et al reported minor adverse events (flushing, chest 
discomfort, dyspnoea) in 27% of 362 adenosine perfusion CMR scans at a dose of 
140mcg/kg/min, and no major adverse events [196].  Studies using higher doses 
(350mcg/kg/min – 500mcg/kg/min) for vasoreactivity testing in PAH patients reported higher 
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rates of minor adverse events (flushing, chest discomfort, dyspnoea) [92, 93, 113, 190],  but 
major adverse events remained rare.  A significant decrease (> 20%) in systemic arterial 
pressure has been reported in 2 of 104 patients in one  study [113], and less frequently 
elsewhere [92, 93, 190, 197].   
 
Rationale for the dosing regimen of the present study (70mcg/kg/min, increasing in 
70mcg/kg/min increments every 3-4 minutes to a maximum dose of 210mcg/kg/min, unless 
limited earlier by side effects) is: 
 Permit dose-response relationships to be interrogated; 
 Ensure maximal hyperaemia is achieved (maintain sensitivity to detect a 
‘clinically meaningful’ response); and, 
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Pulmonary arterial hypertension (PAH) represents a late stage of progressive 
microcirculatory remodelling, or ‘pulmonary vascular disease’ (PVD).  Earlier detection of 
PVD should improve prognosis with current therapies, although validated, non-invasive 
methods to do so remain elusive.  We postulated that changes in pulmonary arterial blood 
flow velocity or pulsatility in response to standardised intravenous (IV) adenosine infusion, 
measured using cardiac magnetic resonance imaging (CMR), would provide a novel and non-
invasive means to measure ‘cardiopulmonary reserve’, providing proof-of-concept for the 
detection of pre-clinical PVD.   
 
Methods  
Patients with known or suspected PAH and a clinical indication for a right heart catheter 
(RHC) and matched healthy volunteers were studied. Exclusion criteria were <18 years old, 
pregnancy, a high cardiac output (CO) state, mean pulmonary arterial wedge pressure 
(mPAWP) > 15mmHg, or a contraindication to CMR or adenosine.   
 
RHC (invasive arm) and CMR (non-invasive arm) were performed within 48 hours.  
Measurements (RHC: mean pulmonary arterial pressure [mPAP], mean pulmonary arterial 
wedge pressure [mPAWP], CO by thermodilution, and pulmonary vascular resistance [PVR]; 
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CMR: phase-contrast imaging through the pulmonary trunk to calculate average pulmonary 
blood flow velocity [meanPAvel] and pulsatility) were taken at rest and during intravenous 
adenosine infusion (after 2 minutes at each dose: 70-, 140-, and 210mcg/kg/min).  PAH was 
confirmed (PAH group, n=17) or excluded (High Risk group, n=9) using standard resting 
haemodynamic criteria.  Age and sex matched healthy volunteers underwent CMR only 
(Control group, n=10).   
 
Results 
Invasively, the High Risk group had greater dose-dependent haemodynamic changes with 
adenosine: PVR reduction 18%8% greater (P<0.05) due predominantly to CO augmentation 
(27%13% greater, P<0.05) rather than transpulmonary gradient reduction (TPG = mPAP–
mPAWP; 5.7%9% greater, P=0.57). Correlation between CMR-derived meanPAvel and 
haemodynamic measurements (positive with CI, negative with mPAP /PVRI) was strong at 
rest and throughout adenosine infusion (R2>0.32, P<0.05 for all) whereas correlation between 
CMR-derived pulsatility and haemodynamic measurements weakened during adenosine.  
Intra- and interobserver variability was greater for pulsatility compared with meanPAvel. 
 
Differences between group average meanPAvels were smallest at rest (9.72.2cm/s vs. 
14.92.7cm/s vs. 182.5cm/s, PAH vs. High Risk, P<0.0001; HR vs. Control, P=0.02) and 
largest at peak hyperaemia (11.93cm/s vs. 223.4cm/s vs. 33.74.4cm/s, P<0.0001 between 
all) reflecting dose-dependent changes of +2724%, +4829% and +8626% for PAH, High 
Risk and Healthy Control groups respectively (P=0.052 for PAH vs. High Risk; P=0.01 for 
High Risk vs. Healthy Controls).   Receiver operator characteristic analyses revealed 
excellent capacity for meanPAvel at hyperaemia to differentiate between groups (PAH vs. 
High Risk: AUC=0.99; High Risk vs. Controls: AUC 1.0).  No dose-dependent relationship 
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were identified between haemodynamic changes and changes in pulsatility, and diagnostic 
performance of pulsatility was inferior to that of meanPAvel.   
 
Conclusion 
CMR-derived meanPAvel is safe and feasible surrogate measure of pulmonary 
haemodynamic changes during standardized adenosine infusion, with meanPAvel at 
hyperaemia performing excellently as a functional correlate for cardiopulmonary reserve 
across a spectrum of clinical risk phenotypes.    This may provide a means to detect pre-




















Pulmonary arterial hypertension (PAH) is a progressive disease characterised by a 
pathological increase in the resistance of the pulmonary circulation, predominantly due to 
obliterative remodelling of the microvasculature (‘pulmonary vascular disease’, PVD).  
Owing to abundant reserve, symptoms and haemodynamic abnormalities remain absent until 
most of the functional microcirculation has been irreversibly damaged, contributing to the 
poor prognosis that persists despite recent therapeutic advances. Earlier disease detection 
should confer prognostic advantage using available disease-modifying therapies, a notion 
supported by registry data [145].  However, current screening of high-risk patient groups 
remains reliant on the non-invasive identification of deranged pulmonary haemodynamics or 
their impact on the right ventricle (RV), rather than targeting the impaired physiologic 
reserve that undoubtedly precedes these findings.   
 
Presently, there is no validated method to detect PVD before measureable haemodynamic 
changes arise (‘early’ PVD).  Borderline pulmonary hypertension (resting mean pulmonary 
arterial pressure (mPAP) of 21-24mmHg) has been associated with higher PAH incidence in 
scleroderma patients [198], but further research is required to clarify the natural history in a 
more diverse patient group.  Exercise induced pulmonary hypertension is backed by sound 
pathophysiological rationale and may suggest a pre-clinical stage of the disease, although the 
exact definition and implications of a ‘pulmonary hypertensive response’ remain to be 
elucidated [199] [14, 48]. Furthermore, while a non-invasive method is preferable, 
acquisition of data by echocardiography can be technically demanding and susceptible to 
imprecision [200, 201]. In PAH patients, a greater response to pulmonary vasodilators at the 
time of diagnostic right heart catheter (RHC) has been associated with an improved prognosis 
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across a range of subtypes [97-100, 202], and while a definitive explanation remains elusive, 
this may in part relate to greater reserve. To date there are no published reports of non-
invasive pulmonary vasoreactivity tests.  
 
We hypothesised that a standardised non-invasive pulmonary vasoreactive protocol utilising 
intravenous (IV) adenosine and cardiac magnetic resonance imaging (CMR) would permit 
quantification of pulmonary vasoreactivity, so that subjects with confirmed PAH, suspected 
but excluded PAH (high risk for incident disease) and healthy controls would display 
discrepant responses.  If observed, this tool may enable the detection of PVD across a 
spectrum of patients with clinical and pre-clinical pathology. 
 
MATERIALS AND METHODS 
 
Study Population 
Subjects with known or suspected PAH and a clinical indication for a right heart catheter 
(RHC) were recruited through a single tertiary-referral centre. Exclusion criteria were age 
<18 years old, pregnancy, known or suspected PAH due to congenital heart disease with 
systemic-to-pulmonary shunt or portopulmonary hypertension, or a contraindication to CMR 
or IV adenosine.  Broad inclusion criteria were applied to reflect a contemporary referral 
population and to permit recruitment of participants across a spectrum of PVD severity.  
Right heart catheterization for suspected PAH was deemed clinically indicated by pulmonary 
hypertension experts following a comprehensive review of clinical status and ancillary 
investigations, in accordance with guidelines [40]. 
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Participants underwent RHC and PAH was confirmed or excluded by standard 
haemodynamic criteria (mean pulmonary arterial pressure, mPAP, >25mmHg; mean 
pulmonary arterial wedge pressure, mPAWP, <15mmHg; and pulmonary vascular resistance, 
PVR >3 Woods units, WU).  All participants with a mPAWP <15mmHg underwent 
vasoreactive testing with IV adenosine, and a CMR scan within 48 hours.  Participants with 
mPAWP > 15mmHg were excluded and did not undergo vasoreactive testing. Age and sex 
matched volunteers were recruited and underwent the CMR component only.  All participants 
provided written informed consent and protocols were approved by the local Research Ethics 
Committee.   
 
RHC 
Participants avoided caffeine for 48 hours prior. Right heart catheterisation was performed 
under light sedation and without supplemental oxygen via the right femoral vein, using a 7 F 
Swan-Ganz thermodilution pulmonary artery catheter (Edwards Lifesciences, California, 
USA).  Comprehensive haemodynamic assessment was undertaken in accordance with 
guidelines [25].  Systemic arterial pressures were monitored via direct arterial measurement 
with a second fluid-filled pressure transducer, or arm cuff if arterial access was unavailable. 
A blood sample was taken for the assessment of N-terminal pro brain natriuretic peptide 
(NTpBNP) levels and centrifuged within 1 hour at 2800rpm for 10 minutes, and stored at -
80C until analysis using a commercially available ELISA kit (USCN Life Science, Texas, 
USA).   
 
Intravenous adenosine (Adenoscan, 3mg/mL, Astellas Pharma, Tokyo, Japan) was 
administered via peripheral venous access (antecubital fossa) as a continuous infusion at 
three increasing doses: 70-, 140-, and 210mcg/kg/min. Haemodynamic assessment (PAP, 
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Cardiac MR imaging was performed using a 1.5 Tesla magnet (Magnetom, Siemens, 
Erlangen, Germany). Cine images of the atria and ventricles were acquired by steady-state 
free precession (SSFP) sequences, and were reconstructed into 25 cardiac phases to allow 
volumetric and functional analyses. Flow imaging was performed perpendicular to the main 
pulmonary artery during free-breathing, approximately 1.5-2cm above the level of the 
pulmonic valve, using a velocity-encoded gradient echo sequence with an upper velocity 
limit of 150cm/sec, temporal resolution 39ms, spatial resolution 1.8x1.8x6mm, 20 
phases/cardiac cycle (Figure 1).  Non-invasive pulmonary vasoreactivity testing was 
conducted using the same protocol as during RHC.  Systemic blood pressure, arterial oxygen 
saturation, and heart rate (HR) were all non-invasively monitored during the infusion.  Flow 
imaging was repeated after a minimum of 2-minutes infusion at each dose.  
 
Images were analysed offline using specialised software (CMR42, Circle Cardiovascular 
Imaging Inc., Calgary, Canada).  Biventricular endocardial and epicardial contours were 
manually drawn at end-diastole and end-systole.  Right ventricular trabeculations and left 
ventricular papillary muscles were excluded from the blood pool.  Atrial volumes were 
measured at end-systole.  Main PA blood flow was measured by manually outlining the inner 
perimeter of the vessel at all 20 reconstructed cardiac phases, reflecting an entire cardiac 
cycle. The key parameters of interest during adenosine infusion were the mean pulmonary 
arterial blood flow velocity across the cardiac cycle (meanPAvel, Figure 1) and PA pulsatility 




Categorical values are expressed as percentage, and normally distributed continuous variables 
expressed as means  standard deviations. Continuous variables were compared using 
Student t test or one-way analysis of variance (ANOVA).  Scatterplots were visualized and 
Pearson correlation coefficients used to explore strength of linear relationships between 
meanPAvel/pulsatility and invasive haemodynamic parameters, and Spearman correlation 
coefficients used to explore strength of curvilinear relationships where there was a departure 
from Gaussian distribution.   Receiver operating characteristic curve analysis investigated 
non-invasive detection of participant groups by CMR parameters, with areas under the curve 
compared using the method described by Hanley and McNeil [203]. Intra- and inter-observer 
variability was assessed using Bland-Altman analysis.  A P value of <0.05 was considered 
statistically significant.  Statistical analyses were performed using a software package 





Forty-one participants were recruited (known or suspected PAH n=31, healthy volunteers 
n=10) and 5 excluded (mPAWP > 15mmHg n=4; claustrophobia n=1).  PAH was confirmed 
in 17 participants (PAH group: incident PAH n=8, prevalent PAH n=9) and excluded in 9 
participants.  For the purpose of this study, these participants were labelled ‘high risk’ for 
incident PAH (possible early PVD, ‘High Risk’ group) because of unexplained 
breathlessness (n=9), high prevalence of connective tissue disease (scleroderma n = 5; 
systemic lupus erythematosus n =1), disproportionately reduced pulmonary diffusing 
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capacity for carbon monoxide, elevated NT-pro brain natriuretic peptide levels without 
myocardial or renal dysfunction, and ‘borderline’ abnormal resting haemodynamics (resting 
mPAP 21-24mmHg, n = 2).  Demographic and clinical characteristics are presented in Table 
1.   
 
Safety and tolerability 
Side-effects with adenosine were similar between groups.  Facial flushing (84%), dyspnoea 
(81%), chest tightness (76%), and mild nausea (43%) were most common.  Infusion was 
ceased prior to protocol completion in 2 participants (1 due to temporary, self-limiting sinus 
bradycardia; 1 due to severe nausea).  There were no major adverse events.   
 
Invasive pulmonary haemodynamics (‘invasive arm’) 
 
Rest 
Compared with the High Risk group, pulmonary pressures (diastolic, systolic, mean) and 
PVR were significantly higher in the PAH group, but there no significant between-group 
differences in RAP or CI at rest.  Resting pulmonary haemodynamics were similar between 
‘incident’ and ‘known’ PAH participants. Mean PAP was outside the accepted normal range 
in 4 High Risk participants (between 21-24mmHg) [42].  
 
Adenosine stress 
Greater dose-dependent haemodynamic changes were observed in response to IV adenosine 
in the High Risk group compared with the PAH group (Figure 2).  Pulmonary vascular 
resistance decreased by 47%23% vs. 29%16% respectively (difference of 18%8%, 
P<0.05), due predominantly to greater augmentation of CI (+59%30% vs. +32%30%; 
 82 
difference of 27%13%, P<0.05) rather than decline in transpulmonary gradient (TPG = 
mPAP - mPAWP; -9% 18% vs. -15%30%, P=0.57). Stroke volume index (SVI) and HR 
increased in both groups to drive CI augmentation, although HR increased significantly more 
in the No PAH group (28%7% greater, P<0.05).  A small but statistically significant rise in 
mPAWP (+2.6  2.7mmHg) was observed in the High Risk group although the mean value 
during maximal hyperaemia remained <15mmHg (13  2mmHg at 210mcg/kg/min).  There 
were no significant changes in systemic blood pressure in either group. A summary of these 
findings is provided in Table 2.    
 
Cardiac magnetic resonance imaging (‘non-invasive arm’) 
 
Rest 
Volumetric CMR parameters revealed significantly lower RVEF, higher RV mass index, and 
greater indexed RA volume in the PAH group compared with High Risk and Healthy Control 
groups, but no significant differences between High Risk and Healthy Control groups. 
MeanPAvel was the only parameter to vary significantly between all groups (9.72.2cm/s vs. 
14.92.7cm/s vs. 182.5cm/s for PAH, High Risk and Healthy Control groups respectively; 
PAH vs. High Risk and High Risk vs. Healthy Control P<0.05).  Pulmonary artery pulsatility 
was significantly lower in the PAH group than both other groups, but there was no significant 
difference between High Risk and Healthy Control groups (209% vs. 4314% vs. 4914% 
respectively; PAH vs. High Risk P<0.05; High Risk vs. Healthy Control P=NS).  Left 
ventricular moyocardial mass, left atrial volume, and LVEF were similar between all groups.  




A linear, dose-dependent increase in meanPAvel was observed in all groups during adenosine 
stress (Figure 3 and Supplement Table 3).  The magnitude of increase was significantly 
greater in the High Risk group compared with the PAH group (meanPAvel at rest 
14.92.7cm/s vs. 9.72.2cm/s respectively and meanPAvel at maximal hyperaemia 
21.73.4cm/s vs. 11.93.3cm/s respectively; 1/linear regresseion slope = 90 vs. 30 
respectively; P<0.0001 for all), and significantly greater in the Healthy Control group 
compared with both other groups (meanPAvel at rest 182.5cm/s and meanPAvel at maximal 
hyperaemia 33.74.3cm/s; 1/linear regression slope =13; P<0.0001 compared to other 
groups).  No clear dose-response relationship in PA pulsatility was observed and there were 
no significant between-group differences in the relative change in pulsatility between rest and 
maximal hyperaemia (Table 2).  Intra-observer and inter-observer variability was small for 




Correlation between CMR flow-imaging parameters and invasive haemodynamics 
 
Rest 
Strong, inverse, curvilinear relationships were found between meanPAvel with PVR (R=-
0.86, P<0.0001) and mPAP (R=-0.76, P<0.0001), and a moderate, positive, linear 
relationship observed between meanPAvel and CI (R=0.66, P<0.0001).  There was no 
correlation between meanPAvel and mPAWP (R=-0.05, P=NS).   Moderate-strong 
correlation between pulsatility and haemodynamic parameters was also observed with similar 
inverse, curvilinear relationships with PVR (R=-0.74, P<0.0001) and mPAP (R=-0.69, 
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P<0.0001) and positive linear relationship with CI (R=0.65, P<0.0001).   Correlation 
coefficients are presented in Table 3 and scatterplots in Figure 4. 
 
Adenosine stress 
Correlation remained strong during adenosine infusion between meanPAvel and 
haemodynamic parameters, but weakened between pulsatility and haemodynamic parameters. 
(Table 3).   
 
Non-invasive discrimination between groups  
 
PAH vs. High Risk 
At rest, meanPAvel (area under the ROC curve, AUC: 0.98, CI 0.94 – 1.02) and pulsatility 
(AUC: 0.95, CI 0.88 – 1.01) showed excellent diagnostic performance and were unchanged 
when only ‘incident’ PAH participants were analysed.  There was a non-significant 
improvement in the AUC for meanPAvel at peak hyperaemia (AUC: 0.99, CI 0.96 – 1.01, 
P=NS vs. meanPAvel at rest), and a non-significant decrease in the AUC for pulsatility at 
peak hyperaemia (AUC: 0.86, CI 0.72 – 1.00, P=NS vs. pulsatility at rest).    
 
High Risk vs. Healthy Controls 
At rest, meanPAvel demonstrated good diagnostic capacity (0.81, CI 0.61 – 1.01) 
whereas diagnostic performance with pulsatility was poor (AUC 0.63, CI 0.36 – 0.90). 
Diagnostic performance of meanPAvel at peak hyperaemia was excellent and significantly 
better than meanPAvel at rest (AUC 1.0, CI 1.0 – 1.0, P = 0.03 vs. meanPAvel at rest). No 
significant change in the AUC was found for pulsatility at peak hyperaemia (AUC 0.57, CI 





Adenosine, administered intravenously, promotes preferential pulmonary over systemic 
vasodilation via endothelial-independent mechanisms at the proximal microcirculatory level 
where PVD predominates, causing CO augmentation without direct inotropic effect [91, 93, 
113] [87, 92] .  Haemodynamic changes during IV adenosine therefore reflect 
microcirculatory dilatation/recruitment, the capacity of the RV to augment flow in response 
to afterload reduction, or a combination thereof.  ‘Microcirculatory reserve’ is likely to 
govern the magnitude of haemodynamic response early in the disease course whereas in more 
severe PAH, ‘RV reserve’ may also contribute (inotropic and/or chronotropic).  Both are 
important and intricately linked, hence the term ‘cardiopulmonary reserve’. 
 
Invasively, average haemodynamic changes in response to adenosine in the High Risk group 
exceeded those in the PAH group, confirming greater cardiopulmonary reserve.  Previous 
studies have demonstrated a prognostic advantage associated with greater haemodynamic 
improvement during vasoreactivity testing in established PAH patients not meeting 
traditional cut-offs for a ‘true’ vasoreactive response (i.e. reduction in mPAP by≥10mmHg to 
a mPAP ≤40mmHg with preserved or increased CO), suggesting a relatively greater 
vasoreactive response may reflect a phenotype with more vasoconstriction, less vascular 
remodelling and, hence, greater vascular reserve [96] [97] [98] [99] [100] [202] [7].   The 
greater PVR reduction with adenosine in the High Risk group was driven primarily by greater 
CO augmentation which, in turn, was driven by a greater rise in heart rate.  It is unclear 
whether this reflected an appropriate physiologic response to discrepant degrees of 
pulmonary microvascular recruitment, or whether autonomic dysfunction in the PAH group 
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may have played a role.  Autonomic dysfunction is described in PAH and associated with 
exercise intolerance and ventilatory inefficiency [204, 205] [206], and a failure to increase 
HR during exercise has been linked with poor survival [207] [208]. 
 
In agreement with a pre-clinical study [83], strong correlation between CMR-derived 
meanPAvel and haemodynamic parameters was found throughout adenonsine-stress, 
suggesting this may be an appropriate clinical surrogate marker of haemodynamic changes 
during vasoreactive testing. Since meanPAvel is thought to slow due to microvascular 
obstruction (PVD), PA dilation and RV systolic dysfunction [82], it is unsurprising that 
significant between-group differences in meanPAvel were observed at rest.  Importantly, 
between-group differences increased during adenosine-stress and were greatest during 
maximal hyperaemia, suggesting meanPAvel at peak hyperaemia performs as an excellent 
functional correlate for cardiopulmonary reserve across a spectrum of clinical risk 
phenotypes, as determined by ‘traditional’ haemodynamic (rest and vasoreactive response), 
clinical and biomarker characteristics.   The non-linear, inverse relationship between 
meanPAvel and PVR (Figure 4) makes meanPAvel at peak hyperaemia a compelling non-
invasive parameter to apply to the detection of ‘early’ PVD since early in the disease course 
(low PVR), any adenosine-induced PVR reduction will be magnified by a relatively greater 
meanPAvel increase, as illustrated by the divergence of High Risk and Healthy control 
groups in the present study.  Finally, we postulate that the superior diagnostic performance of 
meanPAvel at peak hyperaemia over the relative change in meanPAvel may be due to the 
impact of ventilation-perfusion matching, hypoxic vasoconstriction or anxiety at rest, which 
are ameliorated at peak hyperaemia. 
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Reduced global arterial compliance and increased local PA stiffness are recognized early 
changes in PAH and have been shown to be predict mortality, response to vasoreactivity 
testing, and functional capacity as determined by 6MWD [58, 60, 63], and may directly 
contribute to disease progression by promoting downstream vascular remodelling [63]  [60] 
[69].  In the present study, pulsatility was significantly lower at rest in the PAH group but no 
significant difference between High Risk and Control groups was found. Since RV pulsatile 
afterload is known to vary inversely with the resistive afterload in a non-linear fashion, we 
hypothesized that pulsatility would increase during adenosine-stress in proportion to PVR 
reduction, but no dose-dependent change in pulsatility was observed during adenosine-stress.  
This may be due to susceptibility of this parameter to small changes in imaging plane and 
manual measurement (as suggested by intra- and inter-observer variability), or 





Key limitations of this study are the small sample size, single-centre design, and lack of 
clinical outcome measures. The small sample size and large number of measured parameters 
which exhibit co-linearity precludes multivariate analyses.  Participants with suspected but 
excluded PAH were labelled high risk for incident PAH (possible pre-clinical PVD), which 
can only be validated by long-term follow-up.  The dosing regimen for this study was 
proposed to standardise exposure, achieve hyperaemia, and ensure clinically meaningful 
responses would not be missed, although it is possible that other doses may have been more 
appropriate.  Our findings should therefore be considered hypothesis generating until larger 






This study demonstrates safety, feasibility and proof-of-concept for a standardized, novel, 
non-invasive method to assess cardiopulmonary reserve as it pertains to PVD and its’ 
sequelae, PAH, using CMR-derived measurement of mean pulmonary arterial blood flow 
velocity during adenosine-induced hyperaemia.  Sound rationale, non-invasive acquisition, 
ease of measurement, and robust inter- and intra-observer variability should facilitate larger 
validation trials.  If confirmed, such a tool should afford the earliest possible detection of 


















Figure 1: Reference sequences for flow imaging were two double-oblique orthogonal views 
acquired by SSFP along the main axis of the pulmonary trunk (a.).  Flow imaging was 
performed perpendicular to the pulmonary trunk (b.) and repeated at all doses of adenosine 
infusion, allowing measurement of flow and magnitude related variables.  A typical flow 
velocity profile is shown at rest (c.) and during hyperaemia (d.).  Mean PA velocity was 





Figure 2: Haemodynamic changes at peak hyperaemia compared with rest.  
PVR = change pulmonary vascular resistance, CI = change cardiac index, TPG = change 
transpulmonary gradient (mPAP-mPAWP), SVI = change stroke volume index, HR = 
change heart rate.   








Figure 3: Change in meanPAvel during adenosine infusion (a.).   Between-group differences 
were smallest at rest (b.) and greatest at peak hyperaemia (c.).  








Figure 4: Scatterplots illustrating the relationship between meanPAvel and invasive 
haemodynamic parameters measured at rest.   
PVR = pulmonary vascular resistance, CI – cardiac index, mPAP = mean pulmonary arterial 












Participants, n 17 9 10  
Female (%) 13 (76) 7 (78) 8 (80) 0.98 
Age, years 54.314 60.214 46.912 0.13 
Height, cm 162.612 164.19 165.67 0.75 
Weight, kg 73.719 7814 70.311 0.58 
BSA, m2 1.780.25 1.840.14 1.780.16 0.75 
PAH aetiology (%) 
    Idiopathic 




   
Comorbid conditions (%) 
    Diabetes mellitus 
    Smoking 













NYHA functional class (%) 
    II  











    Endothelin receptor antagonist 
    Phosphodiesterase-5 inhibitor 





   
6MWD, m 400104 48059  0.07 
NTpBNP, pg/ml 

















Table 1. Demographic and clinical characteristics of participants. 
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BSA = body surface area, CTD = connective tissue disease, 6MWD = 6-minute walk 
distance, NTpBNP = N-terminal pro-brain natriuretic peptide, DLCO = diffusing capacity for 
























  PAH High Risk Healthy Control 
Rest Hyper Change  
(%) 
Rest Hyper Change 
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Table 2: RHC and CMR-derived parameters at rest and during adenosine-induced 
hyperaemia (Hyper). 
SBP = systemic blood pressure; PVR = pulmonary vascular resistance; mPAP = mean 
pulmonary arterial pressure; CI = cardiac index; mPAWP = mean pulmonary arterial wedge 
pressure; RAP = right atrial pressure; meanPAvel = mean pulmonary arterial blood flow 
velocity; RVEF = RV ejection fraction; LVEF = left ventricular ejection fraction; RVmassI = 
indexed RV mass; RAvolI = indexed RA volume. 
*P<0.05, **P<0.005, ****P<0.0001 for High Risk vs. PAH; †P<0.05, ††††P<0.0001 for 




























meanPAvel CI 0.66*** 0.59** 0.72**** 0.69*** 
mPAP -0.76**** -0.80**** -0.77**** -0.77**** 
PVR -0.86**** -0.83**** -0.86**** -0.86**** 
Pulsatility CI 0.65*** 0.58** 0.44* 0.35 
mPAP -0.69**** -0.71**** -0.74**** -0.62** 




Table 3:  Correlation coefficients for phase-contrast CMR parameters vs. haemodynamic 
parameters at rest and during adenosine infusion (for PAH and High Risk groups). 















Parameter Intra-observer variability Inter-observer variability 
 Mean bias 95% limits of 
agreement 
Mean bias 95% limits of 
agreement 
Pulsatility 10 -30 - 45 14 -40 – 63 
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No unified method exists to effectively predict and monitor progression of PAH.  We 
assessed the longitudinal relationship between a novel marker of cardiopulmonary reserve 
and established prognostic surrogate markers in patients with pulmonary vascular disease.   
 
Methods and Results 
Twenty participants with confirmed (n=14) or at high risk (n=6) for PAH underwent cardiac 
magnetic resonance imaging (CMR) at baseline and after ~6 months of guideline-appropriate 
management.  Ten PAH participants underwent RHC within 48hours of each CMR.  RHC 
(mean pulmonary arterial pressure, mPAP; pulmonary vascular resistance index, PVRI; 
cardiac index, CI) and phase-contrast CMR (mean pulmonary arterial blood flow velocity, 
meanPAvel) measurements were taken at rest and during continuous adenosine infusion 
(70/140/210 mcg/kg/min).  Initial meanPAvel’s (rest and hyperemic) were correlated with 
validated surrogate prognostic parameters (CMR: RV ejection fraction, RVEF; RV end 
systolic volume indexed, RVESVI; RHC: PVRI, CI; biomarker: NT-pro brain natriuretic 
peptide, NTpBNP; clinical: 6-minute walk distance, 6MWD), a measure of pulmonary 
arterial stiffness (elastic modulus) and volumetric estimation of RV ventriculoarterial (VA) 
coupling.  Changes in meanPAvel’s were correlated with changes in comparator parameters 
over time.   
 
At initial assessment, meanPAvel at rest correlated significantly with PVRI (inversely), CI 
(positively) and elastic modulus (inversely) (R2>0.37, P<0.05 for all), whereas meanPAvel at 
peak hyperaemia correlated significantly with PVRI, RVEF, RVESVI, 6MWD, elastic 
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modulus and VA coupling (R2>0.30, P<0.05 for all).  Neither resting or hyperaemia-derived 
meanPAvel correlated with NTpBNP levels.  Initial meanPAvel at rest correlated 
significantly with RVEF, RVESVI, CI and VA coupling at follow up assessment (R2> 0.2, 
P<0.05 for all) and initial meanPAvel at peak hyperaemia correlated with RVEF, RVESVI, 
PVRI and VA coupling (R2>0.37, P<0.05 for all).  Change in meanPAvel at rest over time 
did not show statistically significant correlation with change in prognostic parameters, while 
change in meanPAvel at peak hyperaemia did show a significant relationship with RVEF, 
RVESVI, NTpBNP and CI (R2>0.24, P<0.05 for all). 
 
Conclusion 
MeanPAvel during peak hyperaemia correlated with invasive, non-invasive and clinical 
prognostic parameters at different time points. Further studies with predefined clinical 
endpoints are required to evaluated if this novel tool is a marker of disease progression in 















Pulmonary arterial hypertension (PAH) is characterised by a pathological increase in the 
resistance of the pulmonary circulation secondary to arterial wall remodelling, 
vasoconstriction and in situ thrombosis (pulmonary vascular disease, PVD).  Progressive 
obliteration of the pulmonary vascular bed eventually leads to right ventricular (RV) failure 
and premature death. Therapeutic advances have contributed to better long-term outcomes 
but disease progression remains difficult to predict and objectively monitor necessitating new 
methods.   
 
We previously demonstrated proof-of-concept for a novel non-invasive method to assess 
‘cardiopulmonary reserve’ as it pertains to PAH by measuring the average pulmonary arterial 
blood flow velocity (meanPAvel) at rest and during standardised intravenous (IV) adenosine 
infusion using phase-contrast cardiac magnetic resonance imaging (CMR) [209].  This 
approach to ‘stressing’ the cardiopulmonary unit, whilst novel, was feasible, safe and simple, 
with the results confirming that meanPAvel at peak hyperaemia was an excellent functional 
correlate for cardiopulmonary reserve across a range of clinical risk phenotypes.   
 
As a marker of cardiopulmonary reserve and with the advantage of ameliorating the impact 
of unrelated systemic processes on variables measured at rest, we hypothesised that 
meanPAvel at peak hyperaemia may provide prognostic information at initial assessment and 
during follow up.  To evaluate this, we investigated the association of meanPAvel at rest and 
during peak hyperaemia with accepted RHC-derived, CMR-derived, biomarker and clinical 
prognostic surrogate markers in a cohort of patients with confirmed PAH or at high risk for 
incident PAH.  Specifically, we hypothesised that relative to meanPAvel at rest, meanPAvel 
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at peak hyperaemia at initial assessment would be more closely associated with comparator 
parameters at initial and follow-up assessments, and that changes in meanPAvel at peak 





We prospectively recruited participants with known or suspected PAH and a clinical 
indication for a right heart catheter (RHC) through a single tertiary-referral centre over a 14-
month period (2013-2014).  Patients were ineligible if they were <18 years old; pregnant; had 
known or suspected PAH due to congenital heart disease with left-to-right shunt, or 
portopulmonary hypertension; or, had a contraindication to CMR or IV adenosine.  Right 
heart catheterization for suspected PAH was deemed clinically indicated by pulmonary 
hypertension experts following a comprehensive review of clinical status and ancillary 
investigations, in accordance with guidelines [40]. All participants provided written informed 
consent and protocols were approved by the Local Institutional Research Ethics Committee. 
 
At initial assessment, all participants underwent a RHC and CMR with IV adenosine within 
48hours, with PAH confirmed by haemodynamic criteria (mean pulmonary arterial pressure, 
mPAP, >25mmHg; mean pulmonary arterial wedge pressure, mPAWP, <15mmHg; and 
pulmonary vascular resistance, PVR >3 Woods units, WU).  Participants with mPAWP > 
15mmHg were excluded and did not undergo vasoreactive testing. Patients with PAH were 
invited to undergo repeat RHC and CMR with vasoreactivity testing and participants with 
suspected but excluded PAH (high-risk for incident PAH) invited to undergo repeat CMR 
with vasoreative testing approximately 6 months after their initial study. Between 
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assessments, patients were administered guideline-appropriate management, where 
appropriate. 
 
Right heart catheterization was performed via the right femoral vein with a 7 F Swan-Ganz 
thermodilution pulmonary artery catheter (Edwards Lifesciences, California, USA).  
Systemic arterial pressures were monitored by arm cuff.  Complete resting haemodynamic 
assessment was performed in accordance with current guidelines. Intravenous (IV) adenosine 
(Adenoscan, 3mg/mL, Astellas Pharma, Tokyo, Japan) was infused via peripheral vein at 
three increasing doses: 70-, 140-, and 210mcg/kg/min, and repeat haemodynamic assessment 
(mPAP/mPAWP/CI/PVR) conducted after a minimum of two minutes’ infusion at each dose.  
 
Cardiac magnetic resonance imaging was performed with a 1.5 Tesla magnet (Magnetom, 
Siemens, Erlangen, Germany) with images obtained at end-expiration.  Volumetric and 
functional analyses were performed using steady-state free procession (SSFP) sequences of 
the atria and ventricles.  Flow imaging through the main pulmonary artery was performed 
1.5-2cm above the pulmonary valve using a velocity-encoded gradient echo sequence with an 
upper velocity limit of 150cm/sec, temporal resolution of 39ms and spatial resolution of 
1.8x1.8x6mm. Adenosine was infused using the same protocol as during RHC, with flow 
imaging through the pulmonary trunk repeated after a minimum of 2 minutes at each 
adenosine dose.  Analyses were performed offline using specialized software (CMR42, Circle 
Cardiovascular Imaging Inc., Calgary, Canada).  Ventricular endocardial and epicardial 
contours were manually outlined at end-diastole and end-systole to permit calculation of 
ventricular volumes and myocardial mass by Simpson’s method. Blood flow through the 
pulmonary trunk was measured by outlining the endovascular border at all 20 reconstructed 
cardiac phases permitting calculation of mean pulmonary arterial blood flow velocity 
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(meanPAvel), elastic modulus (pulse pressure x minA/(maxA-minA)) and a volumetric 
estimation of ventriculoarterial (VA) coupling (RVESV/RV stroke volume) [210].  All 
participants underwent 6-minute walk tests and had blood samples taken for NT-proBNP 
quantification, which was centrifuged within 1 hour for 10 minutes at 2800rpm, and stored at 
-80C until analysis using an ELISA kit (USCN Life Science, Texas, USA).   
 
Treatment Strategy 
The objective was to assess the relative strength of association of meanPAvel measured at 
rest and at peak hyperaemia with comparator surrogate prognostic parameters.  Treatment of 
participants with PAH was at the discretion of treating physicians and in line with current 
guidelines [7].   
 
Comparator Surrogate Prognostic Parameters 
Comparator surrogate prognostic parameters for initial and serial analyses were defined a 
priori as: 1) CMR-derived:  right ventricular ejection fraction (RVEF) and right ventricular 
end systolic volume index (RVESVI); 2) Biomarker: NT-proBNP levels; 3) RHC-derived: 
pulmonary vascular resistance index (PVRI) and cardiac index (CI); 4) Clinical: six-minute 
walk distance (6MWD).  In addition to these validated serial prognostic parameters, two 
other physiologically-relevant parameters were assessed: a marker of pulmonary arterial 
stiffness (elastic modulus; at initial assessment only), and volumetric estimation of VA 





Normally distributed continuous variables were expressed as means  standard deviations. 
Normality was assessed using the Shapiro-Wilk normality test. Scatterplots of univariate 
associations were reviewed and, where appropriate, Pearson correlation coefficients were 
used to explore the strength of linear relationships between meanPAvel at rest and during 
hyperaemia with comparator prognostic parameters and Spearman correlation coefficients 
were used to explore the strength of relationships that were curvilinear and where there was a 
significant departure from a Gaussian distribution.  More specifically, meanPAvel measured 
at rest and during hyperaemia at the initial assessment were correlated with initial and follow 
up comparator parameters; and changes in meanPAvel at rest and during hyperaemia were 
correlated with changes in comparator parameters between initial assessment and follow up. 
Statistical analyses were performed using a software package (GraphPad Prism version 6.0, 





Thirty-one participants were recruited (PAH n=19; suspected but excluded PAH: ‘High Risk’ 
n=12) of which 5 were ineligible (mPAWP>15mmHg n=4; claustrophobia n=1).  20 
underwent repeat investigations (PAH n=14; High Risk n=6) after a median period of 8 
months and 21 days (loss to follow-up in PAH group: death from RV failure n=1; 
geographical relocation n=1; declined n=1, and High Risk group: geographical relocation 
n=2; intercurrent illness n=1) and were included in the present study.  Ten of the 14 PAH 
participants had both repeat CMR and RHC and 4 had CMR only (declined repeat RHC n=4). 
Demographic and clinical characteristics of participants are presented in Table 1, with 
suspected but excluded PAH participants considered high risk for incident PAH on the basis 
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of the high prevalence of connective tissue disease, unaccounted for exertional breathlessness 
with disproportionately reduced lung diffusing capacity, elevated NTpBNP levels in the 
absence of left ventricular myocardial disease or renal dysfunction, elevated estimated 
pulmonary arterial systolic pressure by transthoracic echocardiography >40mmHg (n=6) and 
‘borderline’ abnormal resting haemodynamics (n=2 with rest mPAP of 21-24mmHg) [42].   
 
Mean absolute values of comparator, investigational and other relevant parameters, and their 
relative changes over time, are summarised in Table 2.  
 
Response to adenosine 
The haemodynamic and meanPAvel changes in response to adenosine are shown in Figure 1.  
Systemic blood pressure (SBP) did not change significantly during adenosine (systolic SBP -
613% and 018% for PAH and High Risk groups respectively, P=0.38 and 0.23 
respectively – not displayed graphically).  There was minimal intra-observer and 
interobserver variability for meanPAvel measures (mean bias: -0.01 and -0.0000238; 95% 
limits of agreement: -0.21–0.19 and -0.27–0.27 respectively) at all doses.  
 
Correlation between mean pulmonary arterial blood flow velocities and prognostic 
parameters measured at initial assessment 
Correlation coefficients are presented in Table 3.  MeanPAvel at rest showed strong positive 
correlation with CI and very strong negative correlation (curvilinear) with PVRI.  There was 
moderate but statistically insignificant correlation with CMR indices (negative with RVESVI 
and positive with RVEF, Figure 3) and 6MWD (positive), but no correlation with NTpBNP.  
Elastic modulus, a measure of the pressure change required to drive a relative change in the 
PA lumen size, showed strong negative correlation with meanPAvel at rest.  Volumetric 
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estimation of ventriculoarterial coupling showed moderate strength negative correlation with 
meanPAvel at rest.  Therefore a high effective arterial elastance:maximal systolic elastance 
ratio (estimated here by CMR-derived RVESV/RVSV), suggestive of RV-pulmonary 
uncoupling, was associated with lower meanPAvels.  Relative to meanPAvel at rest, 
meanPAvel at hyperaemia correlated more closely with all parameters except RHC-derived 
CI at rest and NTpBNP. 
 
Given the weaker association between CI and meanPAvel at peak hyperaemia, compared to 
meanPAvel at rest, we assessed the relationship between meanPAvel’s and haemodynamic 
measurements made during hyperaemia.  In this regard, meanPAvel at rest and during 
hyperaemia correlated closely with the maximum CI (R=0.60, P=0.005 and R=0.65, P=0.002 
respectively) and minimum PVRI (R=-0.67, P=0.001 and R=-0.74, P=0.0002 respectively) 
during adenosine challenge.  This is consistent with earlier work demonstrating close 
correlation between meanPAvel and invasively-derived haemodynamics at rest and during 
adenosine infusion [211].   
 
Correlation between initial mean pulmonary arterial blood flow velocities and follow up 
prognostic parameters 
MeanPAvel measured at rest showed moderate strength statistically significant correlation 
with RVEF (Figure 3), RVESVI and VA coupling at follow up.  Strong negative correlation 
with follow up PVRI and positive correlation with follow up CI were found.  In contrast, 
there was weak and statistically insignificant correlation with follow up NTpBNP levels and 
no correlation with 6MWD. MeanPAvel measured during peak hyperaemia correlated more 
closely with all parameters except resting CI (R = 0.67 vs. 0.59 for meanPAvel at rest vs. 




Correlation between changes in mean pulmonary arterial blood flow velocities and changes 
in comparator prognostic parameters  
There were no statistically significant associations between change in meanPAvel measured 
at rest and change in comparator prognostic parameters, although statistical power was 
reduced with regard to RHC-derived parameters owing to fewer follow-up invasive 
procedures (n=14 vs. n=10).  In contrast, change in meanPAvel measured at hyperaemia 
correlated moderate-strongly with all comparator prognostic parameters except 6MWD, 
PVRI and VA coupling (R=0.30, P=0.30/R=-0.39, P=0.27/R=-0.44, P=0.06 respectively).  
Similar trends were seen when only confirmed PAH participants were analysed.  Correlation 
coefficients are presented in Table 5. 
 
Despite its routine use, 6MWD has many limitations as a serial prognostic marker (e.g. day-
to-day variation, learning effect and comorbidities), with registry data showing a decline in 
6MWD confers a worse prognosis but a rise in 6MWD has no impact on survival [212].  In 
those participants with a decline in 6MWD (N=9) in the present study, correlation with 
change in meanPAvel at hyperaemia improved but statistical significance was not met (R = -
0.52, P = 0.22) possibly due to the low sample size.    
 
DISCUSSION  
Blood flow velocity through the main pulmonary artery is thought to decline in PAH due to 
impeded passage of cardiac output through remodelled microcirculation, dilation of proximal 
pulmonary vessels and eventually, impaired RV function [82].  Not surprisingly therefore, 
mean pulmonary arterial blood flow velocity (meanPAvel) measured at rest has been shown 
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to correlate with measures of RV function, arterial load and exercise capacity, which are all 
important determinants of prognosis in PAH   [82] [78] [83] [81] [213].  This study adds to 
our knowledge by demonstrating correlation between our non-invasive measure of 
‘cardiopulmonary’ reserve (meanPAvel at peak hyperaemia, [211]) and validated invasively 
and non-invasively derived surrogate prognostic markers at baseline and six month follow-
up. This marker was superior to meanPAvel when measured at rest. These data would 
support further studies being undertaken with hard clinical endpoints, to establish if this 
novel marker would provide incremental prognostic information in patients with PAH or at 
high risk for incident PAH.  
 
PAH is principally defined by the plexogenic pulmonary vasculopathy that underlies its 
genesis, increasing RV afterload and stress. These two compartments (the RV and pulmonary 
vasculature) are integrally related and not surprisingly therefore, measures of RV afterload 
(static e.g. PVR, and oscillatory e.g. pulmonary arterial stiffness, components), stress (e.g. 
NTpBNP), and functional adaptation (e.g. RVEF, RVESVI) all provide independent 
prognostic information.  In isolation however, each parameter tends to provide a limited 
picture of the state of the ‘cardiopulmonary’ unit as a whole. In our study, meanPAvel at 
peak hyperaemia correlated significantly with measures of RV afterload (e.g. PVRI and 
elastic modulus), RV functional adaptation (e.g. RVEF/RVESVI) and VA coupling (defined 
as the ratio of maximal systolic RV elastance: effective arterial elastance), suggesting a 
capacity to simultaneously interrogate the pulmonary vasculature, the RV, and their 
interaction in a simple, non-invasive fashion.  The capacity to assess the RV and pulmonary 
vasculature as a collective unit may translate to improved ability to discriminate changes in 
ventricular function, arterial load, or both when compared to, for example, RVEF, a serial 
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CMR measure that conveys consistent prognostic information in PAH patients [132, 133, 
210].   
 
‘Traditional’ prognostic parameters are generally measured at rest and are subject to the 
influence of unrelated systemic factors such as anxiety, hypertension and sedation which may 
be compounded by serial assessment.  Moreover, they lack the capacity to assess 
physiological reserve, that is, they provide a static measure of a dynamic disease process.  
Our protocol, like other physiological stress tests, negates the influences of unrelated 
systemic factors whilst permitting assessment of reserve as it pertains to PAH, that is, the 
degree of functional pulmonary circulation recruitable by endothelial independent 
mechanisms with IV adenosine (‘vascular reserve’) and the capacity of the RV to increase 
blood flow in response to downstream circulatory recruitment (‘RV reserve’: 
chronotropic/inotropic).   We postulate that the generally closer association found between 
meanPAvel at peak hyperaemia with validated prognostic parameters, compared with 
meanPAvel measured at rest, was due to the capacity to assess the cardiopulmonary unit as 
whole and its’ reserve while ameliorating the impact of unrelated systemic processes.    
 
Acknowledging the above, not all validated prognostic comparators correlated significantly 
with meanPAvel at peak hyperaemia.  Most notably, NTpBNP levels measured at initial 
assessment did not correlate with meanPAvel measured at the same assessment or at follow-
up, although the relative change in NTpBNP correlated with the change in meanPAVel at 
peak hyperaemia over time. Previous studies have demonstrated association between baseline 
NTpBNP levels, resting haemodynamics, lung function, peak VO2 and prognosis, CMR-
derived measures of RV function, and association between change in NTpBNP over time and 
survival [214-217] [218, 219].  The discordant findings of strong correlation between 
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meanPAVel at peak hyperaemia, resting haemodynamics and markers of RV functional 
adaptation (RVEF, RVESVI) but no correlation with NTpBNP levels in absolute terms were 
unexpected and difficult to explain biologically: they may therefore reflect a statistical 
anomaly.  A lack of correlation between change in meanPAvel and change in PVRI over time 
was likely due to the small sample size undergoing repeat RHC (N=10) or, as earlier 
discussed, the impact of unrelated systemic factors on resting measures that may compound 
with serial assessment.  No correlation between change in meanPAvel at peak hyperaemia 
and change in 6MWD over time may reflect the inherent limitations of serial 6MWDs and is 
in keeping with registry data showing a decline in 6MWD is prognostically relevant whereas 
an increase is not [220]. Closer association between these variables in the subset of patients 
that experienced a decline in 6MWD (n=9: R=0.59, P=0.22) is in keeping with our other 
findings, acknowledging that statistical significance was not met, likely due to a small sample 
size.   
 
Study limitations 
The major limitations are the small sample size, single-centre study design, and lack of 
clinical outcome data.  Findings from this study should be considered hypothesis generating.  
Repeat vasoreactivity testing via invasive or non-invasive protocols is novel, with this study 
designed to explore its potential clinical utility by assessing relative strength of association 
across a range of validated prognostic parameters.  Whether meanPAvel provides 
independent prognostic information cannot be determined.  Evidence for potential clinical 
utility of repeat standardised vasoreactivity testing using this protocol is provided by the 
combination of physiologically appropriate correlation across a range of relevant CMR-
derived, RHC-derived, biomarker and clinical variables; and correlation of generally greater 
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strength at hyperaemia compared to rest.  Larger studies are required to confirm these 
findings.   
 
CONCLUSION  
Mean pulmonary arterial blood flow velocity measured using CMR during non-invasive 
standardised pulmonary vasoreactive testing correlated moderate-strongly with a range of 
CMR-derived, RHC-derived, biomarker and clinical prognostic variables at initial assessment 
and at follow up.  Change in meanPAvel at peak hyperaemia on repeat vasoreactivity testing 
correlated with change in these variables over time, although correlation was generally 
weaker.  Compared with meanPAvel measured at rest, correlation was generally stronger 
with meanPAvel measured at peak hyperaemia.  The novel parameter of meanPAvel at peak 
hyperaemia may provide prognostic information by simultaneously interrogating the 
pulmonary vasculature and RV functional capacity whilst ameliorating the impact of 


















Figure 1: Reference sequences for main pulmonary arterial (MPA) phase contrast imaging 
were two double-oblique orthogonal views along the main axis of the pulmonary trunk (a.).  
The endocardial border of the MPA was manually outlined at all 20 reconstructed cardiac 
phases (b. and c.) permitting flow velocity profiles to be generated at rest and hyperaemia (d. 
and e. respectively: flow velocity in ml/s on y axis and time in milliseconds on x axis).  
MeanPAvel was calculated as the average blood flow velocity across all cardiac phases. 






Figure 2: Changes in RHC-derived haemodynamics (panel 1) and CMR-derived meanPAvel 
(initial assessment, panel 2a; follow-up assessment, panel 2b) in response to adenosine in 
PAH and High Risk participants. At RHC, intravenous adenosine produced a dose dependent 
reduction in PVRI driven predominantly by a higher CI rather than a lower mPAP or 
transpulmonary gradient (not illustrated).  At CMR, these changes were reflected by a dose-
dependent rise in meanPAvel. Changes were more pronounced in High Risk participants 







Figure 3: Scatterplots illustrating the relationship between RVEF, meanPAvel at rest and 
meanPAvel at hyperaemia at different time points. 
 
Initial = at initial assessment; Follow-Up = at follow-up assessment; Change = change 











 PAH High Risk P 
value 
Participants, n 14 6  
Female (%) 11 (79) 5 (83) 0.98 
Age, years 5414 637.6 0.18 
BSA, m2 1.790.25 1.830.17 0.79 
PAH aetiology (%) 
    Idiopathic 





Coexisting conditions (%) 
    Diabetes mellitus 
    Smoker 













NYHA functional class (%) 
    II  










Therapy, initial/follow-up (%)          
    Phosphodiesterase-5 inhibitor 
    Combination 
 
1 (7)/0 (0) 
13(93)/14(100) 
  
















 Parameter Group Initial Follow-up Change (%) 
CMR-derived RVEF  
(%) 
PAH 4117 4313 1847 
High risk 607 596 -113 
RVESVI  
(ml/m2) 
PAH 5026 5425 1749 
High risk 247 258 419 
meanPAvel at rest 
(cm/s) 
PAH 9.72.3 10.03.0 527 




PAH 12.23.3 12.96.3 632 
High risk 21.54.3 19.84.9 -88 
RVEDVI 
(ml/m2) 
PAH 8419 9122 815 
High risk 6114 6117 013 
LVEF 
(%) 
PAH 6511 689 521 
High risk 694 666 -39 
RHC-derived CI  
(L/min/ m2) 
PAH 2.350.76  2.590.81 1319 
High risk 2.800.55 n/a n/a 
PVRI 
(WU/ m2) 
PAH 5.53.2 5.33.4 1147 
High risk 1.00.4 n/a n/a 
mPAP 
(mmHg) 
PAH 4616 4814 924 
High risk 194 n/a n/a 
mPAWP 
(mmHg) 
PAH 102 85 330 
High risk 103 n/a n/a 
Clinical/Biomarker NTpBNP 
(pg/ml) 
PAH 23101354 27401361 71200 
High risk 1345718 1289693 -313 
6MWD 
(m) 
PAH 42181 43562 718 




Table 2: Absolute values and relative change in comparator (bold text) and investigational 










[-0.01 to 0.74] 
 
0.055 0.66** 




[-0.71 to 0.09] 
 
0.10 -0.70*** 




[-0.61 to 0.30] 
 
0.44 -0.21 




[-0.93 to -0.57] 
 
<0.0001 -0.88*** 




[0.30 to 0.85] 
 
0.002 0.41 




[-0.04 to 0.74] 
 
0.07 0.58** 






[-0.83 to -0.23] 
 
0.004 -0.65** 
[-0.85 to -0.29] 
 
0.001 
VA coupling -0.49* 
[-0.77 to -0.05] 
 
0.03 -0.75*** 
[-0.90 to -0.46] 
 
0.0001 
Maximum CI 0.60** 
[0.22 to 0.83] 
 
0.005 0.65** 






[-0.90 to -0.47] 
 
0.001 -0.74*** 




Table 3: Correlation coefficients investigating the relationship between meanPAvel and 
comparator parameters measured during initial assessment.   
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[95% confidence interval] 










RVEF 0.47*  
[0.04 to 0.76] 
 
0.04 0.72*** 




[-0.79 to -0.10] 
 
0.02 -0.71*** 




[-0.73 to 0.06] 
 
0.09 -0.42 




[-0.89 to -0.01] 
 
0.05 -0.70* 




[0.11 to 0.90] 
 
0.03 0.59 








[-0.39 to 0.54] 
 
0.71 
VA coupling -0.46* 
[-0.75 to -0.01] 
 
0.04 -0.71*** 




Table 4: Correlation coefficients investigating the relationship between meanPAvel 
measured during initial assessment with follow-up comparator parameters.   














[-0.05 to 0.72] 
0.08 0.63** 
[0.23 to 0.85] 
0.005 
RVESVI -0.23 
[-0.61 to 0.24] 
 
0.34 -0.50* 




[-0.71 to 0.20] 
 
0.26 -0.52* 




[-0.64 to 0.55] 
 
0.84 -0.39 




[-0.14 to 0.85] 
 
0.12 0.62* 




[-0.25 to 0.66] 
 
0.31 0.30 
[-0.27 to 0.72] 
 
0.30 
VA coupling -0.28 
[-0.64 to 0.18] 
 
0.23 -0.44 





Table 5: Correlation coefficients investigating the relationship between changes in 
meanPAvel and changes in comparator parameters over time. 
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Right ventricular (RV) failure is an important cause of morbidity and mortality in pulmonary 
arterial hypertension (PAH).  Pre-clinical studies implicate RV ischemia as a contributing 
cause but our understanding of the relationships between disease burden (resistive and 
pulsatile afterload, AL), coronary status, RV performance, and cardiopulmonary reserve in 




Patients with known or suspected PAH underwent right heart catheterization (RHC) and 
CMR with intravenous adenosine (210mcg/kg/min), and Healthy Controls (n=9) underwent 
CMR only.  PAH was confirmed (n=17) or excluded (n=9, ‘High Risk’ group) by 
haemodynamic criteria. Coronary sinus flow reserve (CSFR) and RHC-derived indexes of 
myocardial blood supply:demand for the RV (PI/TTI) and LV (DPTI/SPTI) were measured. 
CSFR and PI/TTI had a significant direct relationship (R=0.59, P<0.03) and both were 
significantly lower in the PAH group (CSFR: P<0.05 vs. High Risk and Controls; PI/TTI: 
P<0.01 vs. high risk).  DPTI/SPTI was similar between PAH and high risk groups and not 
related to CSFR (R=-0.13).  In PAH and High Risk groups, CSFR and PI/TTI correlated 
significantly with RV AL (distensibility/pulsatility R2≥0.21, P≤0.03; pulmonary vascular 
resistance/mean pulmonary pressure R2>0.37,P<0.03), RV remodelling (indexed RV 
mass/end diastolic and systolic volumes/right atrial volume R2≥0.37, P≤0.03), RV 
performance (RV ejection fraction/ventriculoarterial coupling, R2≥0.52, P≤0.03), and a 
functional correlate for cardiopulmonary reserve (CMR-derived mean pulmonary arterial 
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blood flow velocity during hyperaemia, R2≥0.4, P≤0.03).  DPTI/SPTI did not correlate with 
these parameters.   
 
Conclusion 
CSFR and the myocardial supply:demand index for the RV are decreased in PAH and are 
directly related to disease severity (RV AL), RV remodeling/performance, and a functional 






















Progressive pulmonary vasculopathy is the hallmark of pulmonary arterial hypertension 
(PAH), increasing both resistive and pulsatile components of right ventricular (RV) afterload 
(AL).  The capacity of the RV to adapt to this load is an important prognostic factor.  
Initially, high wall stress promotes adaptive changes which enable matching of ventricular 
performance to arterial load.  Progression of disease ultimately leads to maladaptive 
remodelling, characterized by chamber dilation, eccentric hypertrophy, systolic and diastolic 
dysfunction, and right heart failure (RHF). Pre-clinical studies implicate right ventricular 
ischemia as a contributing cause and potential treatment target [140, 165, 168, 188], but our 
understanding of the relationships between RV workload, RV myocardial perfusion, and RV 
performance in the clinical setting is limited.  
 
In PAH, RV pressurization impacts both myocardial blood supply (reducing the pressure 
index pressure index, PI: difference between aortic and RV pressures throughout the cardiac 
cycle) and ‘demand’ (increasing wall tension which can be approximated by the tension time 
index, TTI: area under the RV pressure curve in systole).  Autoregulation of the coronary bed 
and enhanced myocardial oxygen extraction can compensate but once exhausted, flow 
becomes solely dependent on forward pressure and susceptible to small additional 
perturbations in the supply:demand balance (e.g. exercise, tachycardia, progression of PVD).  
If coronary flow is insufficient, energy-dependent cellular processes will be downregulated to 
restore metabolic balance [164], leading to unsatisfactory RV contractile performance. 
Therefore, a greater understanding of these relationships may be clinically useful.     
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No single study has investigated the relationship between coronary micro- and macrovascular 
status, RV AL, RV remodelling/performance, and cardiopulmonary reserve in the clinical 
setting.  The purpose of this study was to investigate these relationships across a spectrum of 
PVD severity using noncontrast phase-contrast (PC) cine cardiac magnetic resonance 
imaging (CMR) measurement of coronary sinus flow reserve (CSFR) [175] [176, 177], 
haemodynamic measurement of  myocardial blood supply:demand indexes, haemodynamic 
and CMR measures of RV AL and RV remodelling/performance, and a functional correlate 
for cardiopulmonary reserve (mean velocity of blood flow in the main pulmonary artery 
measured during adenosine-induced hyperaemia, hyperemic meanPAvel) [209, 221].  We 
hypothesized that hyperemic coronary flow reserve (CSFR) and the myocardial blood 
supply:demand index for the RV would decline in accordance with RV AL, RV remodelling 
and performance, and cardiopulmonary reserve.   
 
METHODS 
Patients with known or suspected PAH and a clinical indication for a right heart catheter 
(RHC) were prospectively enrolled from a single tertiary-referral centre over a 14-month 
period (2013-2014).  Exclusion criteria were <18 years old; pregnancy; known or suspected 
PAH due to congenital heart disease with left-to-right shunt, or portopulmonary 
hypertension; a mean pulmonary arterial wedge pressure (mPAWP) >15mmHg; stenosis 
>50% in any non-branch coronary artery; or, a contraindication to CMR or intravenous (IV) 
adenosine.   The clinical decision to perform a RHC was made by treating pulmonary 
hypertension physicians in accordance with guideline-directed practices after review of 
appropriate ancillary investigations [222].   Age and sex matched healthy volunteers were 
also enrolled. The study protocol conforms to the ethical guidelines of the 1975 Declaration 
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of Helsinki as reflected in a priori approval by the Local Institutional Research Ethics 
Committee, and participants provided written informed consent. 
Participants with known or suspected PAH underwent RHC and CMR with IV adenosine 
within 48 hours. PAH was confirmed by haemodynamic criteria (mean pulmonary arterial 
pressure [mPAP] >25mmHg, mPAWP <15mmHg, pulmonary vascular resistance [PVR] >3 
Wood units [WU]).  Healthy controls underwent CMR with IV adenosine only.   
 
Right heart catheterization was performed via the right femoral vein using a 7 F Swan-Ganz 
thermodilution catheter (Edwards Lifesciences, California, USA).  Standard resting 
haemodynamic measurements were made and cardiac output (CO) measured by 
thermodilution in triplicate.  Systemic arterial pressures were measured throughout the 
procedure by arm cuff.  Diagnostic coronary angiography was performed via the right 
femoral or radial artery (if not conducted at our institution within the preceding 3 years).    
 
CMR images were obtained at end expiration using a 1.5 T magnet (Magneton, Siemens, 
Erlangen, Germany).  Steady-state free procession (SSFP) sequences of the atria and 
ventricles were acquired for volumetric/functional analyses.  Phase-contrast (PC) imaging of 
the coronary sinus (CS; upper velocity limit of 50 cm/sec, temporal resolution of 8.6 
milliseconds, 20 phase per cardiac cycle, Figure 1) and main pulmonary artery (PA; 1.5cm 
above the pulmonic valve; upper velocity limit of 150cm/sec, temporal resolution of 39ms, 
spatial resolution of 1.8x1.8x6mm, 20 phase per cardiac cycle) was performed at rest and 
during adenosine-stress (at a dose of 210mcg/kg/min).  Analyses were performed offline 
using specialized software (CMR42, Circle Cardiovascular Imaging Inc., Calgary, Canada).  
Ventricular endocardial and epicardial borders were outlined manually at end-diastole and 
end-systole to calculate volumes and myocardial mass using Simpson’s method. Atrial 
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volumes were measured at end of ventricular systole.  The endovascular border of the CS and 
PA were manually outlined in all twenty reconstructed cardiac phases to calculate CS and PA 
flows. CSF was adjusted to biventricular mass to provide coronary blood flow per milligram 
of myocardium per minute.  CSFR was calculated by dividing CSF measured during 
adenosine-induced hyperaemia (CSFstress, ml/mg/min) by CSF at rest (CSFrest , ml/mg/min).  
Mean pulmonary arterial blood flow velocity (meanPAvel) at hyperaemia was calculated by 
averaging velocities across all twenty reconstructed cardiac phases during adenosine-stress 
(hyperemic meanPAvel, cm/sec).   Pulsatility and distensibility of the main PA were 
calculated at rest using the following formulae: 
 
(1) Pulsatility =  [maxPAarea –minPAarea]/maxPAarea * 100 
 
(2) Distensibility  =  [(maxPAarea - minPAarea)/PP x min PAarea] * 100  
where maxPAarea and minPA area are the maximum and minimum cross sectional areas of 
the PA during the cardiac cycle and PP is the pulmonary pulse pressure. 
 
Myocardial blood supply:demand indexes were calculated using the following rationale and 
formulae: 
1.  Right ventricle (PI/TTI) 
Coronary blood flow to the RV (‘supply’; PI) occurs during systole and diastole and is the 
product of the coronary perfusion pressure (CPP) and duration of each phase.  Systolic 
CPP (sCPP) reflects the difference between systemic systolic pressure (SSP) and RV 
systolic pressure (RVSP), and diastolic CPP (dCCP) the difference between systemic 
diastolic pressure (SDP) and RV diastolic pressure (RVEDP). Systolic time is typically 
fixed at ~200ms with the remaining time occupied by diastole: 
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o PI = (sCPP x systolic time) + (dCPP x diastolic time)   
 sCPP = (SSP – RVSP) x 0.2s 
 dCPP = (SDP – RVEDP) x ([60s/heart rate] – 0.2s) 
 
‘Demand’ is reflected by the area under the RV systolic pressure curve (TTI), the product of 
RV systolic pressure and systolic time: 
o TTI = RVSP x 0.2s 
 
2. Left ventricle (DPTI/SPTI) 
Coronary bloody flow to the LV (‘supply’; DPTI) occurs during diastole only and is the 
product of the CPP and diastolic time: 
o DPTI = (DSP – LVEDP) x ([60s/heart rate] – 0.2s) 
 
‘Demand’ is the area under the LV systolic pressure curve (SPTI): 
o SPTI = SSP x 0.2s 
 
Continuous variables are expressed as mean ± SD.  Normality was assessed using the 
Shapiro-Wilk normality test and outliers identified using the ROUT method (Q=1%). 
Unpaired t-tests were used to compare differences between groups with a two-sided P value 
of <0.05 considered statistically significant. RHC and CMR-derived parameters of interest 
were selected a priori: RV AL (resistive: mPAP, PVR; pulsatile: PA pulsatility and 
distensibility); RV remodeling/performance (all volume and mass measures indexed to 
BSA: RV mass [RVmassI], RA volume [RAvolI], RV end diastolic volume [RVEDVI], RV 
end systolic volume [RVESVI], RV ejection fraction [RVEF], and a volumetric estimation of 
ventriculo-arterial [VA] coupling [ratio of effective arterial elastance, Ea, to maximal systolic 
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ventricular elastance,Emax, calculated by: RVESV/RV stroke volume] [210]; 
cardiopulmonary reserve (meanPAvel during hyperaemia); myocardial blood 
supply:demand indexes (RV: PI/TTI, LV: DPTI/SPTI).  Scatterplots were visualized and 
Pearson correlation coefficients used to explore strength of linear relationships between 
CSFR and normally distributed comparator parameters, and Spearman correlation 
coefficients used to explore strength of curvilinear relationships where there was a departure 
from Gaussian distribution.   Relationships between CSFR and all comparator parameters 
were explored, whereas myocardial blood supply:demand indexes were related only to CMR-
derived parameters and PVR (due to being directly intertwined with other RHC-derived 
parameters).  To account for multiple comparisons, a P value <0.03 was considered 
statistically significant.  Statistical analyses were performed using a software package 





Forty-one participants (31 known or suspected PAH, 10 healthy controls) were recruited for 
this study. Five patients and 1 healthy control were excluded (mPAWP >15mmHg n = 4; 
claustrophobia n = 1; intolerant to maximum dose adenosine n = 1). PAH was confirmed in 
17 participants (PAH group) and excluded in 9 participants.  For the purpose of this study, 
these participants were labelled ‘high risk’ for incident PAH (possible early PVD, ‘High 
Risk’ group) because of unexplained breathlessness (n=9), high prevalence of connective 
tissue disease (scleroderma n = 5; systemic lupus erythematosus n =1), disproportionately 
reduced pulmonary diffusing capacity for carbon monoxide, elevated NT-pro brain natriuretic 
peptide levels without myocardial or renal dysfunction, and ‘borderline’ abnormal resting 
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haemodynamics (resting mPAP 21-24mmHg, n = 2)[42]. Demographic and clinical 
characteristics are presented in Table 1.  
 
CSF and myocardial supply:demand indexes  
CSFR was significantly lower in the PAH group compared with High Risk and Healthy 
Control groups (1.7 ± 1.2 vs. 2.9 ± 1.4 and 3.1 ± 1.1, P = 0.02 and 0.006 respectively, Figure 
1).  There was no significant difference in CSFR between High Risk and Control groups.  
Mean CSFrest was highest in the PAH group (1.0 ± 0.5 vs. 0.7 ± 0.3 and 0.8 ± 0.3 
respectively, P = NS), although statistical significance was not met. 
 
PI/TTI was significantly lower in the PAH group compared with the High Risk group (3.6 ± 
2.1 vs. 10.8 ± 2.3, P<0.0001) but there was no difference in DPTI/SPTI (1.6 ± 0.4 vs. 1.6 ± 
0.4, P=NS, Table 2 and Figure 3).  Considering ‘supply’ (PI and DPTI) and ‘demand’ (TTI 
and SPTI) independently, there were significant differences in both PI and TTI between 
groups (P<0.002 for both, data not presented) but no differences in DPTI or SPTI (P=NS for 
both, data not presented).   
 
A significant positive linear correlation was evident between CSFR and PI/TTI (R = 0.59, P 
= 0.002), but no correlation between CSFR and DPTI/SPTI (R = -0.13, P = 0.54).  
 
Comparator parameters  
Absolute values and correlation coefficients are presented in Table 2.  All parameters were 
significantly different between PAH and High Risk groups except RVEDVI (P = 0.25) and 
DPTI/SPTI (P = 0.79).  CSFR correlated significantly with all parameters except DPTI/SPTI.  
Relationships with mPAP, PVR, RVmassI, RAvolI, RVESVI, RVEF, and VAcoupling were 
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non-linear, with perturbations in comparator parameters becoming much more marked below 
a CSFR of ~2, whereas RVEDVI and hyperemic meanPAvel varied in a linear fashion with 
CSFR (Figure 4).   
 
PI/TTI correlated significantly with all comparator parameters except RVEDVI (P=0.04) 
(Table 2).  Like CSFR, PI/TTI varied in a non-linear fashion with PVR, RVmassI, RAvolI, 
RVESVI, RVEF, and VAcoupling, with marked perturbations found in subjects with a 
PI/TTI of <~5 (Figure 5).  Pulsatility and hyperemic meanPAvel declined linearly with 
PI/TTI .  No correlation between DPTI/SPTI and comparator parameters was found (R<0.30, 




Prognosis in PAH is closely linked to the capacity of the RV to maintain cardiac output in the 
presence of a rising afterload.  Clinical symptoms such as a declining functional capacity, 
syncope and chest pain in patients with PAH can signal that cardiac reserve is exhausted.   
Pre-clinical and clinical studies suggest that inadequate coronary blood flow to a severely 
pressurized RV may contribute to contractile dysfunction and RV failure [140, 165, 168-171, 
178, 188].  The present study supports this by showing that coronary flow reserve and the 
right ventricular myocardial blood supply:demand index are lower in PAH subjects, and are 
related to resting measures of afterload, remodelling, and performance of the RV.  It adds to 
prior knowledge by demonstrating a non-linear, threshold-type relationship between coronary 
perfusion and ventriculo-arterial coupling (ratio of effective arterial elastance to maximal 
systolic ventricular elastance), and a linear relationship with a functional correlate for 
cardiopulmonary reserve.  These findings suggest that inadequate RV coronary perfusion 
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may contribute to a limited cardiopulmonary reserve at an earlier disease stage, and to 
uncoupling of the RV-PA circuit when PVD is more severe.   
 
Right ventricular workload rises with PVD progression, increasing metabolic and (therefore) 
oxygen demands.     Coronary perfusion must increase to meet these demands and avoid 
pump failure.  However, unique physiology dictates that RCA driving pressure is 
concomitantly reduced by RV pressurization (lower systolic and diastolic pressure gradients 
between the aorta and RV which may be compounded by systemic hypotension in advanced 
disease), and systolic epicardial RCA flow may be restricted by compression [169], further 
limiting supply.  Clinical and experimental studies suggest that compensatory mechanisms 
such as microvascular dilation [140, 188, 223], increased myocardial capillarization [153], or 
improved mechanical efficiency [180], have limited capacity to overcome coronary 
supply:demand imbalance so that, inevitably, contractile function must be sacrificed to 
maintain perfusion-contraction matching [164, 224].  This sequence of events has been 
confirmed in experimental studies (with the capacity to systematically manipulate 
physiologic parameters) but limited evidence of this is available in the clinical setting. 
 
By examining relationships between RV AL, RV performance/ and remodelling, and 
cardiopulmonary reserve across a range of PVD severities we could explore their interaction 
in relation to disease progression.  In earlier disease (that is, lower resistive afterload or 
PVR), PI/TTI and CSFR decreased in relation to the pulsatile but not resistive RV AL.  This 
is consistent with the well-defined inverse relationship between resistive (resistance, R) and 
pulsatile (compliance, C) afterloads of the pulmonary circulation (which dictates that C is 
compromised to a greater degree than R in early PVD), and the fact that pulsatile afterload 
contributes significantly to total RV AL (~25% of total AL in contrast to ~10% in the 
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systemic circulation) [56, 66].  With disease progression, we observed a continued decline in 
CSFR and PI/TTI as well as evidence of RV remodelling (increased RVEDVI, RVESVI, and 
RVmassI), but relatively preserved RV performance (RVEF, VAcoupling).  We postulate 
that compensatory mechanisms (e.g. coronary vasodilation, increased capillarization, RV 
hypertrophy mitigating wall tension etc.) at this point are sufficient to meet the higher 
metabolic demands of the pressurized RV, enabling contractility to overcome AL at rest. The 
higher myocardial blood flow at rest in the PAH group, while not statistically significant, 
supports this and is consistent with earlier work by Dubiel et al. which demonstrated higher 
myocardial blood flow and lower coronary vascular resistance in the RV of patients with 
moderate PH [185]. 
 
In more advanced disease, we observed a consistent inflection point (at a PI/TTI <5 and 
CSFR ~< 2) after which disease progression had little further impact on PI/TTI or CSFR, but 
a marked impact on RV remodelling and performance.  This is best illustrated by examining 
the relationship between coronary perfusion (both CSFR and PI/TTI) and ventriculo-arterial 
coupling (Figure 3), which has the advantage of reflecting changes in total RV AL, RV 
performance, or both [210, 225].  We hypothesize that at (and beyond) this inflection point or 
‘threshold’, compensatory mechanisms in the coronary vascular bed are maximized so that 
small additional perturbations in perfusion (e.g. progression of PVD) render oxygen supply 
inadequate for the metabolic needs of the RV, leading to contractile dysfunction and 
uncoupling of Emax from Ea, but maintenance of perfusion-contraction matching.  Pre-clinical 
studies have shown that supraphysiologic coronary perfusion can restore RV performance 
despite a severely elevated AL [140, 165, 188], but clinical studies exploring direct 
manipulation of coronary perfusion parameters in ambulatory PAH patients are lacking. 
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Mean PA blood flow velocity at hyperaemia performs as a functional correlate for 
cardiopulmonary reserve, incorporating both the vascular (‘vascular’ reserve) and ventricular 
(‘RV reserve’, inotropic and chronotropic) components of the right heart-lung unit [209, 
221].  Unlike the curvilinear relationships between coronary perfusion, RV AL, and RV 
performance/remodelling parameters measured at rest, we found a linear inverse relationship 
between mean PA blood velocity at hyperaemia and coronary perfusion parameters (Figure 
3).  We postulate that myocardial oxygen delivery may not increase sufficiently to meet the 
higher metabolic requirements of physiologic stress, leading to relative contractile 
dysfunction and a limited ‘RV reserve’, even in subjects without severe PVD as determined 
by traditional resting RHC- and CMR-derived parameters.   Gomez et al. found scintigraphic 
evidence of exercise-induced subendocardial RV ischemia in a subgroup of PAH patients 
with severe disease [170], but to the best of our knowledge, the present study is the first to 
link RV coronary perfusion perturbations with physiologic reserve at an earlier disease stage.   
 
Implications 
Findings from the present study suggest that in advanced PVD, RV contractile dysfunction 
and uncoupling of the RV-PA circuit may in part be due to an insufficient myocardial blood 
supply (and hence oxygen supply) relative to demand.   Given PVD is progressive despite 
pulmonary vasodilator therapy, and lung transplantation is not uniformly suitable or 
available, therapeutically targeting determinants of RV myocardial oxygen supply, demand, 
and utilization by means supplementary to lowering PVR may improve RV metabolic and 
contractile potential, even in the face of a persistently high AL. Since heart rate is a major 
determinant of RV oxygen demand [179], selective sinus node If  channel inhibition 
(ivabradine) may be beneficial and is supported by small studies in PAH and PH-lung disease 
patients, although mechanisms underlying the observed clinical improvement are not clear 
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[226, 227]. Increasing myocardial capillary density [228], ameliorating autonomic 
dysregulation [229], and mitigating mitochondrial dysfunction [230, 231] may be alternative 
approaches.  Lastly, easily accessible measures of RV perfusion parameters (e.g. PI/TTI) may 
assist in the assessment of clinical risk in PAH patients.   
 
Study Limitations 
The small sample size, single-centre design, and lack of clinical outcome measures are major 
limitations. It is not possible to determine causation (between RV AL and coronary perfusion, 
and coronary perfusion and RV remodelling/performance/cardiopulmonary reserve) from our 
data, as was illustrated in pre-clinical studies.  Our findings are consistent with existing pre-
clinical and clinical work and are supported by sound pathophysiologic rationale, but should 
be considered hypothesis generating until larger trials powered to explore the independent 
clinical value of measuring/manipulating coronary perfusion are conducted.  In calculating 
PI/TTI, we did not consider the wall tension or oxygen carrying capacity of the blood 
(haemoglobin level), systemic BP was measured by arm cuff rather than invasively, and a 
fixed systolic time of 200ms was used in place of a calculated systolic time interval using 
regression equations proposed by Weissler et al [232].  While systematic error may have 
been introduced, observed between-group differences or correlation coefficients should not 
have impacted.  Furthermore, Wong et al. showed that adding wall stress to HR and PASP 
(which are incorporated in our PI/TTI calculation) did not improve association with RV 
myocardial oxygen consumption [179], and haemoglobin levels were similar between patient 
groups. Minor epicardial coronary artery disease or microvascular dysfunction unrelated to 
PAH/PVD (e.g. diabetes mellitus, connective tissue disease) may have influenced CSFR 
measures.  This impact is thought to be small as subjects with epicardial stenoses >50% were 
excluded, and no difference in CSFR between CTD-PAH and iPAH was found (data not 
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presented).  Finally, the coronary sinus does not transport coronary efflux from all vascular 
territories, including the anterior cardiac veins.  Our results support CSFR relating 
predominantly to alterations in RV myocardial blood supply/demand in this population given 
the lack of association between LV-derived parameters across both groups.  
 
CONCLUSION   
 
The present study provides insights on the relationships between RV AL, micro- and 
macrovascular coronary status, RV remodelling/performance, and cardiopulmonary reserve, 
demonstrating that RV perfusion declines early in relation to a rising pulsatile afterload, a 
declining cardiopulmonary reserve, but relatively preserved RV structure and performance, 
whereas in advanced PAH, minor perturbations in coronary perfusion are associated with a 
dramatic decline in RV performance and uncoupling of the RV-PA system.  Directly 
targeting RV perfusion parameters may therefore be of therapeutic benefit.     
 














Figure 1: Flow imaging of the coronary sinus (CS).  The CS was identified in the basal short 
axis SSFP images within the atrioventricular groove.  The reference plane for flow imaging 
was parallel to the long axis of the heart, about 0.5cm from the CS ostium.  Velocity encoded 
images were acquired (A and B) at rest and with adenosine (210mcg/kg/min).  Coronary 
sinus flow was measured by tracing the endovascular border at all 20 reconstructed cardiac 
phases, generating a flow velocity profile (C, where the x axis is time in milliseconds and y 
















Figure 2: Differences in coronary sinus flow [CSF, ml/mg/min] measured at rest [CSFrest] 
and during adenosine-stress [CSFstress], and coronary sinus flow reserve [CSFR].   
 
* P<0.05 PAH vs. Healthy Controls 













 CSF and CSFR
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* P<0.05 PAH vs. Control











Figure 3: Differences in myocardial blood supply:demand indexes for the right (PI/TTI) and 
left (DPTI/SPTI) ventricles. 






Figure 4: Scatterplots illustrating relationships between coronary sinus flow reserve 
(CSFR) with markers of RV afterload (blue), RV remodeling/performance (green), 
and cardiopulmonary reserve (orange). 
 






















































































































Figure 5: Scatterplots illustrating relationships between the myocardial 
coronary supply:demand index for the right ventricle (PI/TTI) and markers of 
RV afterload (blue), RV remodeling/performance (green), and 
cardiopulmonary reserve (orange). 
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TABLES 




Participants, n 17 9 9  
Female (%) 13 (76) 7 (78) 8 (89) 0.98 
Age, years 54.314 60.214 46.912 0.13 
Height, cm 162.612 164.19 165.67 0.75 
Weight, kg 73.719 7814 70.311 0.58 
PAH etiology (%) 
    Idiopathic 




   
Comorbid conditions (%) 
    Diabetes mellitus 










NYHA functional class (%) 
    II  











    ERA 
    PDE5i 





   
NTpBNP (pg/ml) 22031350 1555824  0.29 
Creatinine  8121 7534  0.58 










Table 1: Demographic and clinical characteristics of participants.   
  
CTD = connective tissue disease; NYHA = New York Heart Association; ERA = endothelin 
receptor antagonist; PDE5i = phosphodiesterase-5 inhibitor; NTpBNP = N-terminal pro brain 









Table 2: Absolute values of comparator parameters, and correlation coefficients with CSFR 
and PI/TTI. 










47±17 19 ± 4 <0.05 -0.65***  
PVR 
(WU) 
11.5±9.6 1.8 ± 0.8 <0.05 -0.59** -0.93**** 
Distensibility 
(%/mmHg) 
0.5 ± 0.4 2.2 ± 1.1 <0.05 0.54**  
Pulsatility  
(%) 









45 ± 19 28 ± 10 <0.05 -0.82**** -0.67*** 
RAvolI 
(ml/ m2) 
85 ± 38 50 ± 22 <0.05 -0.69*** -0.57** 
RVEDVI 
(ml/ m2) 
88 ± 27 74± 32 0.25 -0.55** -0.40* 
RVESVI 
(ml/ m2) 
49 ± 25 29 ± 15 <0.05 -0.72**** -0.70**** 
RVEF 
(%) 
40 ± 18 61 ± 8 <0.05 0.81**** 0.80**** 










PI/TTI 3.6 ± 2.1 10.8 ± 2.3 <0.05 0.59** 
DPTI/SPTI 1.6 ± 0.4 1.6 ± 0.4 0.79 -0.13 
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mPAP = mean pulmonary artery pressure; PVR = pulmonary vascular resistance; RVmassI = 
indexed RV myocardial mass; RAvolI = indexed right atrial volume; RVEDVI/RVESVI = 
























CONCLUSION AND FUTURE DIRECTIONS 
 
It is peculiar that pulmonary arterial hypertension - which has long been recognized as a 
“plexogenic pulmonary arteriopathy” [233] - continues to be defined by arbitrary, late 
pathophysiologic sequelae (i.e. pre-capillary pulmonary hypertension), particularly since  
certain populations at risk are readily identifiable (e.g systemic sclerosis and other connective 
tissue diseases), and contemporary, disease-modifying medical treatments are most effective 
when instituted early in the disease course.  Furthermore, unlike left ventricular systolic 
dysfunction, there is a distinct lack of therapies specifically targeting the inevitable 
maladaptive right ventricular remodeling and systolic dysfunction that ensues.  We designed 
and tested a novel, noninvasive pulmonary vasoreactive challenge utilizing cardiac magnetic 
resonance imaging and intravenous adenosine to: (i) determine feasibility, safety, and 
tolerability of this novel method to interrogate the right ventricular-pulmonary arterial unit 
(cardiopulmonary unit); (ii) evaluate the capacity of phase-contrast CMR parameters to 
provide surrogate measures of pulmonary haemodynamics at rest and during vasoreactive 
challenge; (iii) explore whether CMR-derived surrogate measures provide insight into the 
reserve of the cardiopulmonary unit across a spectrum of clinical risk phenotypes, thus 
providing proof-of-concept for the detection of early pulmonary vascular disease; (iv) assess 
the capacity to provide longitudinal prognostic insight; and, (v) explore the relationship 
between RV coronary perfusion, maladaptive RV remodeling, systolic dysfunction, and 
cardiopulmonary reserve.  Key findings of this body of work are: 
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 This protocol, utilizing intravenous adenosine infusion (70-, 140-, 210mcg/kg/min; 
3-minutes at each dose) and CMR measurement of mean pulmonary arterial blood 
flow velocity (meanPAvel) is safe, feasible and tolerable. 
 MeanPAvel correlates closely with relevant invasive pulmonary haemodynamic 
measurements at rest and during all doses of adenosine infusion, suggesting it is a 
suitable non-invasive surrogate measure.  Pulsatility correlates with resting 
pulmonary haemodynamics, but correlation weakens during adenosine infusion. 
 Participants with suspected but excluded PAH (labelled as high risk for incident PAH 
– or possible early PVD – for the purposes of this study) have significantly greater 
haemodynamic responses to intravenous adenosine compared to participants with 
PAH. 
 MeanPAvel measured during adenosine-induced hyperaemia is an excellent 
functional correlate for cardiopulmonary reserve (as it pertains to PVD) across a 
spectrum of clinical risk phenotypes as determined by traditional clinical, 
haemodynamic and biomarker parameters, as well as by vasoreactive haemodynamic 
changes.   
 Diagnostic performance of meanPAvel at peak hyperaemia is excellent for the 
discrimination of participants with PAH, high risk for incident PAH, and healthy 
volunteers.   
 MeanPAvel at peak hyperaemia correlates with validated clinical, biomarker, CMR-
derived, and RHC-derived prognostic parameters at initial assessment and 
longitudinally over time. 
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 Right ventricular coronary perfusion parameters (myocardial supply:demand index 
and hyperemic coronary flow reserve) are impaired in PAH and directly related to 
RV remodelling, RV performance, RV afterload, and cardiopulmonary reserve 
 
Acknowledging that validation studies are necessary for any new diagnostic/assessment tool, 
these findings have several potential clinical implications.  It is widely accepted that 
prognosis in PAH remains unacceptably poor despite therapeutic advances over recent 
decades.  Identification of PVD prior to a measureable rise in pulmonary pressures represents 
an important - but thus far elusive – strategy to improve clinical outcomes with available 
therapies. Detecting a depleted cardiopulmonary reserve by assessing pulmonary 
haemodynamic changes during exercise has been widely evaluated without reliable success, 
in part due to difficulties standardizing and performing exercise pulmonary haemodynamic 
tests, understanding the bounds of ‘normal’ physiology, and acquiring measurements via non-
invasive means.  Our studies suggest that meanPAvel can be reliably and reproducibly 
measured non-invasively by CMR, both at rest and during standardized adenosine-stress, 
overcoming some of the limitations of exercise stress testing.  Furthermore, meanPAvel at 
peak hyperaemia performed excellently as a functional correlate for cardiopulmonary reserve 
in participants representing a spectrum of clinical risk phenotypes, providing proof-of-
concept for the detection of PVD before the vascular bed is overwhelmed.  Since current 
therapies mitigate the natural history of PAH, this would be an opportune time to initiate 
treatment.  In established PAH, predicting and monitoring treatment response remains 
difficult despite frequent, comprehensive re-evaluation in expert PAH centres, which may in 
part reflect a reliance upon static, resting measures of the state of the RV-PA circuit. Simple, 
non-invasive, reproducible, quantitative measures of cardiopulmonary reserve should afford a 
dynamic – and more informative - assessment of the RV-PA unit, facilitating more timely 
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treatment decision-making (e.g. transition to intravenous prostanoid therapy or referral for 
lung transplantation assessment).  MeanPAvel at hyperaemia, and its change over time, 
correlated with validated prognostic markers in the present study, but larger trials with long-
term follow up are necessary to determine whether independent and/or superior prognostic 
information is provided by this parameter.  Finally, progression to RV failure and premature 
death seems inevitable without lung transplantation.  We demonstrate a close relationship 
between RV coronary perfusion, RV maladaptive remodelling, systolic dysfunction, and 
uncoupling of the RV-PA circuit.  In addition to lowering PVR with ‘standard’ PAH 
therapies, directly targeting determinants of RV coronary perfusion (e.g. slowing heart rate 
with ivabradine) may support RV performance (and, therefore, overall cardiac performance) 
deeper into the disease course, thereby delaying the major cause of death, RV pump failure. 
 
FUTURE DIRECTIONS 
The presented findings are encouraging and supported by sound rationale, but represent only 
the first step towards the provision of a novel, clinically available diagnostic and assessment 
tool.  CMR is commonly used in established PAH but its application towards detection of 
early PVD is hindered by its relatively high cost and lack of availability compared to, for 
example, trans-thoracic echocardiography (TTE).  Additionally, while our protocol was safe, 
feasible, and tolerable, side-effects related to central effects of adenosine (particularly at 
210mcg/kg/min) were common.  Modification of the protocol to address these limitations 
may facilitate larger validation trials that are the logical ‘next step’.  Further research should 
address: 
1. Modification/adaptation of existing protocol 
o An alternative adenosine infusion regimen may yield similar diagnostic 
performance, but improved tolerance (e.g. 50-, 100-, 150mcg/kg/min).  We 
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demonstrated discrepant dose-dependent increases in meanPAvel between the 
three participant groups during IV adenosine.  While between-group differences 
(and diagnostic performance) was greatest at peak hyperaemia, diagnostic 
performance was good at 140mcg/kg/min (AUC 0.98 PAH vs. High Risk; AUC 
0.94 High Risk vs. Healthy Controls).   Measuring meanPAvel at rest and 
maximal hyperaemia only (i.e. rest and after 2-minutes infusion at 
210mcg/kg/min) may be a feasible alternative. 
o TTE may be capable of measuring meanPAvel which could be investigated by a 
comparative study (same participants undergoing both CMR and TTE).  TTE-
derived meanPAvel may be measured by: 
 acquiring a Pulsed Wave Doppler (PW) sample 1.5-2cm distal to the 
pulmonic valve in the right ventricular outflow view of the parasternal 
short axis window; 
 tracing systolic and diastolic Doppler profiles to yield the meanPAvel 
across the cardiac cycle. 
 CMR measurement of meanPAvel removes the assumption that flow is 
uniform throughout the PA – this may be a limitation of TTE-derived 
meanPAvel. 
2.  Validation of findings and derivation of appropriate cut-offs 
o Larger studies with long-term clinical follow-up are necessary to validate our 
findings.  Specifically, the assumption that our High Risk group represented 
possible pre-clinical PVD can only be validated by such follow-up.  This may best 
be achieved by a registry-type study where patients at risk of incident PAH (e.g. 
systemic sclerosis) undergo routine measurement of meanPAvel at hyperaemia.  
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With sufficient incident PAH cases, derivation of ‘at-risk’ or ‘early PVD’ cut-off 
values should be possible, enabling prospective validation studies.   
o Patients with left ventricular diastolic dysfunction were excluded from our studies.  
It would be important (and interesting) to determine the impact of latent or overt 
heart failure preserved ejection fraction on meanPAvel at hyperaemia, and assess 
whether there is significant variation between pre- and post-capillary diseases. 
o Reproducing and confirming the prognostic role of meanPAvel at hyperaemia in 
established PAH should be more feasible.  With a larger sample size, the 
independent prognostic relevance and cut-off values at baseline and longitudinally 
over time could be evaluated.  This could be conducted as a standalone 
prospective study, part of a prospective therapeutic trial, or as a registry-type 
study.    
3. Comparison with alternative, validated measures of cardiopulmonary reserve in PAH 
o Non-invasive cardiopulmonary exercise testing (CPET) is usually performed 
using an incremental ramp exercise protocol to maximum exercise capacity.  
While protocol standardization is lacking for PAH, typical exercise responses are 
described and peak oxygen uptake (VO2) provides prognostically-relevant 
information that can assist with therapeutic decision making.  Correlation between 
meanPAvel at hyperaemia and peak VO2 (or other relevant CPET-derived 
parameters) in PAH patients would support the pathobiologic rationale for 
meanPAvel at hyperaemia preforming as a functional correlate for 
cardiopulmonary reserve, as outlined in previous Chapters.   
4. Further investigation of the relationship between RV myocardial perfusion and RV failure 
o As discussed in Chapter 5, pre-clinical studies (with the capacity to manually 
manipulate physiologic parameters) clearly support RV ischemia as a cause – 
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and potential treatment target - of RV failure when afterload is elevated.  Our 
findings support these relationships in the clinical setting, but do not permit 
causation be assessed.  The independent prognostic relevance of myocardial 
oxygen supply:demand index (PI/TTI) could be readily interrogated using 
retrospective, registry data since it is calculated using routine haemodynamic 
parameters.  With validation, serial measurement of parameters that influence 
RV coronary perfusion may provide additional markers of disease progression 
and treatment response in ambulatory PAH patients, as well as providing new 
surrogate end-points for relevant therapeutic trials (e.g. medications 
specifically targeting these parameters). 
 
In summary, this body of work comprises the design and rationale of a novel, non-invasive 
approach to the interrogation of the cardiopulmonary unit in the context of pulmonary 
vascular disease, and findings relating to the application of this protocol towards detection of 
early PVD, monitoring disease progression and treatment response in established PAH, and 
elucidating the relationship between right ventricular coronary perfusion, RV performance, 
and cardiopulmonary reserve.  Further research is urgently required to develop a thorough 
understanding of the PVD pathophenotype at all disease stages which, if available, may 
enable substantial improvements in morbidity and mortality using currently available 
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